Medicine News

Latest pharmaceutical research, drug approvals, medication safety updates, and treatment breakthroughs from iMedic.

507 articles

Articles

Breast Cancer Recovery: Can Exercise Improve Attention?

Exercise research offers clues about attention and biological aging after breast cancer, with important limits on what the findings prove.
ACL Surgery Pain: Can Supervised Rehabilitation Help?

Supervised rehabilitation improved short-term recovery in adults with persistent knee problems after ACL reconstruction, but benefits narrowed over time.
Inclisiran: How Does Twice-Yearly Cholesterol Treatment Work?

As cholesterol gene editing advances, explore how inclisiran lowers LDL through RNA silencing, its injection schedule, and its benefits and limitations.
Rentosertib for Pulmonary Fibrosis: What Did Its Trial Show?

Explore rentosertib's early pulmonary fibrosis trial, its lung-function findings, safety concerns and what new aging-marker research adds.
FDA-Approved Drugs: What Does China’s Growing Role Mean?

More recently approved medicines involve manufacturing in China. Learn what the trend means for FDA quality standards, biologics and treatment access.
Evinacumab: Who Benefits From ANGPTL3 Cholesterol Treatment?

Explore how evinacumab targets ANGPTL3 to treat severe inherited high cholesterol, what clinical trials show, and its practical limitations.
Libre Duo: How Can Glucose-Ketone Monitoring Help?

FDA-authorized Libre Duo tracks glucose and ketones together. Explore the evidence, diabetes treatment implications and limits of continuous monitoring.
Colon Cancer Survival: Can Exercise After Chemotherapy Help?

A randomized trial supports structured exercise after colon cancer chemotherapy. Learn what the survival findings mean and how patients can start safely.
AI Analysis of Routine Imaging May Predict Treatment-Induced Lung Inflammation

An AI model may help identify lung cancer patients at risk of serious treatment-induced lung inflammation using routine medical imaging.
AI CT Scans May Predict Immunotherapy Pneumonitis in Lung Cancer

An AI model may identify lung cancer patients at risk of immunotherapy-related pneumonitis using routine pretreatment CT scans.
RNA Therapy Could Help Preserve Muscle During GLP-1 Weight Loss

Experimental RNA therapy may help protect muscle during GLP-1 weight loss, but clinical trials must establish its safety and effectiveness.
Cancer Deaths Decline as New Cases Rise: What Is Driving the Divide?

U.S. cancer deaths continue to fall despite rising incidence, highlighting progress in lung cancer care and persistent prevention challenges.
GLP-1 Prescribing in Normal-Weight Adults Raises Safety and Documentation Questions

A report on GLP-1 prescribing highlights normal-weight use and missing diagnoses, raising questions about safety, oversight and clinical need.
Breztri Triple Inhaler Gains EU Asthma Approval: Who May Benefit?

EU approval expands triple-inhaler treatment for asthma. Learn how Breztri works, who may benefit and which safety issues matter.
Blinatumomab for High-Risk Childhood B-Cell ALL: What the Evidence Shows

Blinatumomab may improve event-free survival in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.
Winrevair and Ibtrozi FDA Updates: What Patients Should Know

FDA activity involving Winrevair and Ibtrozi highlights targeted treatment advances for pulmonary hypertension and ROS1-positive lung cancer.
Nerandomilast for Pulmonary Fibrosis: What Can It Do?

Explore nerandomilast for pulmonary fibrosis, including regulatory approvals, clinical trial benefits, side effects and treatment limitations.
Orphan Drug Exclusivity: Who Can New Approvals Reach?

A revised U.S. orphan-drug exclusivity rule could help developers pursue treatments for additional patient groups. Here is what changes.
Brain Cancer: Could Skull Immune Hubs Improve Treatment?

Immune structures in skull bone marrow helped fight glioblastoma in mice, suggesting a new research direction. Benefits in people remain unproven.
Psilocybin for Depression: What Will FDA Approval Require?

Psilocybin trials show promise for depression. FDA discussions highlight the evidence, safety monitoring and unanswered questions shaping possible approval.
Sprifermin for Knee Osteoarthritis: What Did Trials Show?

Sprifermin trials show why increasing knee cartilage thickness does not automatically mean less osteoarthritis pain or better movement.
Psychedelic Drug Trials: What Evidence Does the FDA Need?

Why psychedelic medicines face unusual FDA review questions involving trial blinding, psychotherapy, safety monitoring and durable benefit.
Small-Cell Lung Cancer: MRI Monitoring Shows Cognitive Benefit

The MAVERICK trial supports brain MRI monitoring without preventive radiation in small-cell lung cancer, although final survival results remain pending.
Sacroiliac Joint Pain: Which Symptoms and Exercises Matter?

Sacroiliac joint pain can resemble sciatica. Learn how clinicians assess it, which exercises may help, and when symptoms need urgent care.
Zenocutuzumab for Pancreatic Cancer: Who May Benefit?

How zenocutuzumab targets rare NRG1 fusions in advanced pancreatic cancer, including FDA approval evidence, testing and safety.
Short-Course Breast Radiation Reduces Treatment Burden and Costs

Shorter breast radiation schedules can reduce clinic visits and costs while maintaining effective early-stage cancer treatment.
Weight-Loss Campaigns Targeting First Nations Women Raise Drug Marketing Concerns

Unbranded weight-loss campaigns targeting First Nations women raise concerns about hidden drug promotion, cultural safety and informed consent.
Newborn IV Nutrition: Standardized or Individualized?

Standardized IV nutrition can support premature babies, but some need tailored prescriptions. Explore the evidence, benefits and monitoring requirements.
Automated Insulin Delivery: Where Do Ketone Sensors Fit?

Continuous ketone monitoring raises new questions for insulin pump care, from device compatibility to backup treatment plans and clinical evidence.
Glioblastoma Vaccines: What Do Early DNA Trials Show?

Personalized glioblastoma vaccines show early immune activity. Explore the DNA vaccine evidence, combination trials and remaining treatment questions.
ANCA Vasculitis: Can Treatment Use Fewer Steroids?

As Tavneos faces scrutiny, established trials explain how lower steroid exposure can fit into ANCA vasculitis treatment and where uncertainty remains.
Libre Duo: What Does FDA Authorization Mean for Diabetes?

Explore Libre Duo's FDA authorization, evidence for glucose and ketone monitoring, and what the new diabetes sensor could mean for patients.
SGLT2 Inhibitors and Ketoacidosis: Why Blood Sugar Can Miss the Risk

New ketone monitoring technology raises a medication-safety question: why can SGLT2 diabetes drugs cause ketoacidosis without very high blood sugar?
First-in-Human Drug Dosing: How Could FDA Models Improve Safety?

FDA draft guidance explores how biological models could improve starting-dose selection for experimental drugs, including complex immune therapies.
Saxenda for Children Under 12: Where Is It Approved?

Explore Saxenda's different U.S. and EU age limits, the childhood obesity trial behind its evidence, and key treatment risks.
Oral vs Topical Minoxidil: Which Works for Hair Loss?

GLP-1 hair-loss concerns raise questions about minoxidil. Explore oral versus topical treatment evidence, safety, and gaps in prevention research.
Prostate Cancer Vaccines and Keytruda: What Did a Trial Find?

A prostate cancer trial tested DNA vaccines with pembrolizumab. Learn what the findings mean for treatment, safety and future research.
Melanoma Vaccine: What Do Phase 3 Results Mean?

A personalized melanoma vaccine has encouraging phase 3 results. Explore the evidence, remaining questions and implications for patients.
Glioblastoma: Could Targeting SET Improve Radiation Response?

Blocking SET prevented glioblastoma formation in experimental models, suggesting a possible way to weaken treatment resistance. Human benefits remain unproven.
Knee Osteoarthritis: Can 3D Cartilage Cells Repair Damage?

Experimental cartilage cell therapy shows early MRI signals in knee osteoarthritis, but larger controlled studies must establish benefits and safety.
Tudriqev for Advanced Melanoma: Who Could Benefit?

FDA-approved Tudriqev combines a tumor-injected virus with nivolumab for resistant melanoma. Explore the evidence, eligibility and safety risks.
Breast Cancer Vaccine STEMVAC: What Are Trials Testing?

STEMVAC breast cancer vaccine trials are testing immune responses and safety. Learn what researchers hope to achieve and what remains unproven.
Antifungal Treatment Advances: Rezafungin and Drug Resistance

Explore rezafungin’s expanded use, antifungal clinical trial evidence, and why drug resistance still complicates treatment of serious fungal infections.
Japan’s Regenerative Medicine Pathways Balance Faster Access and Evidence

How Japan regulates regenerative medicine, including conditional approval, safety oversight and evidence requirements for cell-based treatments.
Injectable Gel Could Extend Osteoarthritis Drug Delivery in Joints

An experimental injectable gel may keep osteoarthritis medicines inside joints for weeks while improving lubrication.
Pediatric Weight-Loss Drug Prescriptions Rise as Doctors Weigh Benefits and Risks

Weight-loss drug use is rising among U.S. children, highlighting potential benefits, side effects and the need for long-term care.
Prescription Weight-Loss Medicines: Eligibility, Benefits and Risks

Learn who may qualify for prescription weight-loss medicines, how the treatments work and why long-term medical follow-up matters.
Robot-Assisted Liver-Kidney Transplant Advances Minimally Invasive Surgery

A robot-assisted liver-kidney transplant highlights the potential and remaining questions surrounding minimally invasive transplant surgery.
Anifrolumab for Cutaneous Lupus: Early Safety Findings Explained

Early findings examine infections and hospital care among people receiving anifrolumab for chronic cutaneous lupus.
Weight-Loss Drugs and Hair Loss: What Genetically Susceptible Men Should Know

New research examines whether GLP-1 weight-loss drugs may modestly increase hair-loss risk in genetically susceptible men.
Experimental Oral Therapy Reduces Obstructive Sleep Apnea Events in Phase 3 Trial

A once-nightly experimental pill reduced breathing events in a phase 3 sleep apnea trial, but CPAP remains established treatment.
Single-Session Lung Cancer Diagnosis, Staging and Surgery Explained

A single-session lung cancer pathway may combine biopsy, lymph-node staging, tumor marking and minimally invasive surgery.
UK Rescinds Tavneos Authorization: What Avacopan Patients Should Know

The UK has rescinded Tavneos authorization. Learn what the decision may mean for people taking avacopan for ANCA-associated vasculitis.
Breast Cancer Fatigue May Be Driven by Depression and Psychological Stress

Research links persistent breast cancer fatigue more strongly to depression and perceived stress than heart injury, informing survivorship care.
High Blood Sugar May Strengthen Cancer’s Shield Against the Immune System

Research suggests high blood sugar may reinforce a sugar-rich coating that helps cancer cells evade immune attack.
FDA National Priority Vouchers Could Accelerate High-Impact Drug Reviews

How the FDA's national priority voucher pilot may shorten selected drug reviews while maintaining evidence and safety standards.
Tally Health Scientist Joins ARDD Meeting as Longevity Drug Research Faces Clinical Test

A Tally Health scientist will speak at ARDD in Boston, spotlighting the evidence needed to turn aging research into validated treatments.
FDA Approves RefluxStop Implant for Gastroesophageal Reflux Disease

FDA approval brings RefluxStop, a noncompressive implant for GERD, to U.S. care as five-year data and postmarket monitoring shape its role.
JAK Inhibitors for Alopecia Areata: How Arthritis Drugs May Restore Hair Growth

Arthritis medicines that block JAK signaling are reshaping severe alopecia areata care, but treatment requires careful safety screening.
Experimental Fat-Burning Drug Preserves Muscle in Obese Mice

An experimental drug reduced fat while preserving muscle in obese mice, but its safety and effectiveness in humans remain unknown.
Smart Nanoparticles Could Detect and Destroy Hidden Glioblastoma Cells

A mouse study suggests smart nanoparticles could illuminate hidden glioblastoma cells and treat microscopic cancer remaining after surgery.
Asthma Inhalers in Early Pregnancy: Study Supports Continued Corticosteroid Use

New findings offer reassurance about inhaled corticosteroid use for asthma during the first trimester of pregnancy.
FDA Authorizes First Continuous Glucose and Ketone Monitor for Diabetes

The FDA has authorized the first wearable system designed to continuously monitor glucose and ketones in people with diabetes.
Could Some Children With Rhabdomyosarcoma Avoid Bone Marrow Biopsies?

Research may help doctors identify children with rhabdomyosarcoma who can safely avoid invasive bone marrow sampling during cancer staging.
Why Exercise May Be More Effective at Preventing Weight Regain

Exercise may have modest effects on initial weight loss but play a larger role in preserving muscle and preventing weight regain.
Mediterranean Diet May Improve Diet Quality Without Extra Weight Loss

A primary care trial suggests a Mediterranean-style diet can improve diet quality even when it does not produce additional weight loss.
Early-Life Sugar Exposure May Influence Adult Cancer Risk

Research links lower sugar exposure during the first two years of life with reduced cancer risk in adulthood, but causation remains uncertain.
Could GLP-1 Weight-Loss Drugs Help Treat Alcohol Use Disorder and Liver Disease?

Researchers are investigating whether GLP-1 weight-loss medicines could help people with obesity, alcohol addiction and liver disease.
Sleep Extension as Clinical Therapy for Insomnia and Metabolic Health

Sleep is emerging as a measurable treatment target alongside CBT-I and insomnia medicines, with potential benefits for mental and metabolic health.
FDA Approves Garetosmab for Fibrodysplasia Ossificans Progressiva

Garetosmab offers a new treatment option for fibrodysplasia ossificans progressiva, a rare disorder that causes bone growth in soft tissues.
Cancer Vaccine Trial Signals New Way to Prevent Tumor Recurrence

A cancer vaccine trial offers encouraging evidence that immune-based treatment may help prevent tumors from returning after initial therapy.
Follow-On Rare-Disease Treatments: How Orphan Exclusivity Shapes Competition

How orphan-drug exclusivity and pediatric development rules influence follow-on therapies, clinical trials, competition, and access.
Rare-Disease Medicines for Children: How New Policy Could Change Trials

New orphan-drug and pediatric policy updates could affect trial planning, incentives and evidence for rare-disease medicines.
Low-Fat Vegan Diet for Weight Loss: What a 16-Week Trial Shows

A randomized trial suggests a low-fat vegan diet may support weight loss without calorie counting, but food quality and nutrients still matter.
Tadalafil for Longevity: What Evidence and Safety Guidance Show

Tadalafil is promoted online for longevity, but clinical evidence does not show that it extends life in healthy people.
How to Preserve Muscle While Taking GLP-1 Weight-Loss Drugs

Learn how resistance exercise, adequate protein and clinical monitoring may help preserve muscle during GLP-1 weight-loss treatment.
Weight-Loss Drugs May Cut Food Spending, but Savings Favor Higher Earners

GLP-1 weight-loss drugs may reduce food spending, but medication costs and unequal coverage mean savings are not shared equally.
Orphan Drug and Pediatric Trial Policy Changes Could Reshape Medicine Development

Federal policy updates could alter incentives, study requirements and development strategies for rare-disease and pediatric medicines.
Orexin-Blocking Insomnia Medicines Expand Options Beyond Traditional Sedatives

How orexin-blocking medicines and cognitive behavioral therapy are changing evidence-based treatment for chronic insomnia.
Precision Sleep Treatment: How CBT-I, Medicines and Monitoring Fit Together

How clinicians combine CBT-I, medicines and monitoring to treat insomnia while limiting next-day impairment and dependence risks.
NIH Body Weight Planner: How Dynamic Calorie Modeling Supports Weight Loss

The NIH Body Weight Planner models how calorie and activity changes may affect weight, offering more realistic guidance than static calorie rules.
Brainstem GIP Receptor May Control Weight Through Opposing Pathways

Mouse research reveals how opposite interventions at a brainstem GIP receptor may reduce weight through distinct biological pathways.
Federal Spending Package Updates Rare-Disease and Pediatric Drug Development

Federal policy updates could affect orphan-drug incentives, pediatric studies, and development plans for treatments addressing unmet needs.
Big Toe Arthritis: Joint Fusion Surgery Reduces Walking Pain in Randomized Trial

A randomized trial found that big toe joint fusion reduced walking pain more than watchful waiting in people with hallux rigidus.
Generic Semaglutide Race Raises Questions About Weight-Loss Drug Quality

The race for lower-cost semaglutide is testing how regulators assess complex peptide drugs, manufacturing quality, and patient safety.
Rare Childhood Blood Cancer Discovery Opens Path to Targeted Treatment

A laboratory breakthrough has revealed a possible route toward targeted treatment for a rare childhood blood cancer.
Higher-Dose Clomiphene Raises Pregnancy Safety Questions in Fertility Treatment

New research links higher clomiphene doses to pregnancy risks, highlighting the importance of individualized ovulation treatment.
New 12-Hour Mucinex Cold and Fever Medicine Wins FDA Approval

FDA approval adds a 12-hour Mucinex option for multiple cold and fever symptoms, with important precautions about overlapping ingredients.
GLP-1 Skincare Claims Grow as Weight Loss Changes Facial Volume

Learn why facial changes can follow GLP-1 weight loss, what skincare can realistically do, and when to seek professional advice.
Dexrazoxane Shows Long-Term Heart Protection After Childhood Cancer

Long-term research links dexrazoxane during chemotherapy to less heart damage in survivors of childhood cancer.
Fructose Signaling May Help Ovarian Cancer Spread After Chemotherapy

Early research suggests chemotherapy-surviving ovarian cancer cells may release fructose signals that help neighboring tumor cells spread.
Can Once-Weekly Exercise Reduce Belly Fat and Central Obesity?

A four-month trial suggests one weekly exercise session may reduce abdominal fat, but broader activity remains important for health.
Orexin Agonist Sleep Drugs Could Transform Narcolepsy Treatment

Takeda’s orexin agonist approval opens a new treatment era for narcolepsy and intensifies research into other sleep-wake disorders.
Why the Brain Resists Weight Loss and Drives Weight Regain

Research explains how brain circuits, hunger hormones and metabolic adaptation can promote weight regain after successful weight loss.
Retatrutide Before FDA Approval: How Patients May Access the Triple-Agonist Weight-Loss Drug

Retatrutide targets GLP-1, GIP and glucagon receptors. Learn what its clinical results and limited pre-approval access mean for patients.
How Gut Bacteria May Turn a Western Diet Into Colorectal Cancer Risk

Research links bacterial production of secondary bile acids to colorectal cancer associated with Western dietary patterns.
KRAS Mutation Testing in Pancreatic Cancer: What New Targeted Drugs Could Change

New KRAS-targeted drugs could expand pancreatic cancer options, but molecular testing and clinical trials remain essential.
FDA-Approved Rituximab Biosimilar Adds a New B-Cell Therapy Option

FDA approval of Dr Reddy’s rituximab biosimilar adds competition for an important B-cell therapy used in cancer and autoimmune care.
Pan-RAS Drugs Could Expand Targeted Treatment for Pancreatic Cancer

Investigational pan-RAS drugs may bring targeted treatment to more people with KRAS-driven pancreatic cancer, but clinical evidence remains essential.
FDA Staffing Strain Raises Risks for Drug Reviews and Safety Oversight

Staff losses and regulatory delays at the FDA could affect drug reviews, safety monitoring and patients awaiting new treatments.
Aging Drug Network Predictions Need Clinical Trials Before Patient Use

Network medicine is identifying existing drugs that may target aging biology, but laboratory predictions are not evidence of longer, healthier lives.
Ivermectin Exposure in Early Pregnancy Shows No Increased Risk in New Study

Research found no increased risk of miscarriage, stillbirth or major congenital anomalies after ivermectin exposure early in pregnancy.
New-Onset Diabetes Patterns May Help Identify Pancreatic Cancer Risk

A long-term cohort study links severe or rapidly progressing new-onset diabetes with increased pancreatic cancer risk.
Generic Prucalopride Approval Could Expand Chronic Constipation Treatment

A new generic prucalopride approval may increase treatment options for adults with chronic idiopathic constipation.
Polymyalgia Rheumatica and Giant Cell Arteritis: Warning Signs That Need Urgent Care

Learn how polymyalgia rheumatica is diagnosed, treated and distinguished from urgent giant cell arteritis symptoms.
Trutakna FDA Approval Adds Dual-Target Treatment for IgA Nephropathy

FDA approval of Trutakna introduces a dual-target therapy for IgA nephropathy, expanding treatment options for this progressive kidney disease.
Replimune Skin Cancer Treatment Faces Renewed FDA Evidence Concerns

FDA reviewers have renewed concerns about evidence for Replimune's experimental skin cancer therapy. Here is what patients should know.
Polymyalgia Rheumatica: Recognizing Symptoms and Starting Treatment

How clinicians recognize polymyalgia rheumatica, exclude similar conditions, use corticosteroids, and monitor for giant cell arteritis.
Acetaminophen With Naproxen Gains FDA Approval for Non-Opioid Pain Relief

FDA approval of acetaminophen with naproxen expands non-opioid pain relief, but liver, stomach, kidney and heart risks remain important.
Enlicitide for High LDL Cholesterol: Who May Benefit and What Evidence Is Still Missing

Enlicitide sharply lowers LDL cholesterol, but treatment decisions must consider dosing, existing therapies and unfinished cardiovascular outcomes research.
FDA Approves 24 Drugs in Record Month: What the Surge Means for Patients

The FDA approved 24 drugs during its busiest month of the year. Learn what the surge means for evidence, safety and patient access.
Peptide Medicine Quality: What Patients Should Check Before Treatment

FDA scrutiny of peptide medicines highlights why product approval, purity, sterility and pharmacy oversight matter for patient safety.
FDA Approves Interchangeable Ranibizumab Biosimilar in Two Delivery Formats

FDA approval of interchangeable ranibizumab-hkdz may expand anti-VEGF treatment options for retinal diseases.
FDA Advisers Support Compounding Access for Four Unapproved Peptides

FDA advisers supported a potential compounding pathway for four unapproved peptides, raising questions about evidence, quality and access.
AI Calorie-Tracking Apps May Underestimate Meals and Fat

AI food-tracking apps may substantially underestimate calories and fat, raising concerns for weight management and clinical nutrition.
Peptide Drugs Face an FDA Regulatory Turning Point

How FDA oversight of compounded and unapproved peptides could affect drug quality, prescribing, patient access and clinical research.
Retatrutide Weight-Loss Data Raise Questions About Cardiovascular Benefit

Retatrutide produces substantial weight loss, but new analyses leave its effect on heart attack, stroke and cardiovascular death uncertain.
Ozempic, Mounjaro and Hair Loss: What the Emerging Diabetes Evidence Means

A large study suggests a small hair-loss risk with Ozempic and Mounjaro, but the finding does not prove these diabetes drugs directly cause it.
GIP Receptor Brain Circuits Could Guide Better Weight-Loss Drugs

Research may explain why activating or blocking GIP receptors can promote weight loss through distinct brain circuits.
Exercise for Hip Osteoarthritis May Improve Pain and Physical Function

Exercise may improve hip osteoarthritis pain and function, although average benefits may be too modest for some patients to notice.
What to Eat on GLP-1 Weight-Loss Drugs: Nutrition and Side-Effect Guidance

Learn what to eat while taking GLP-1 weight-loss medicines to support nutrition, preserve muscle and manage digestive side effects.
Weight-Loss Drug Advertising Dispute Tests Semaglutide and Tirzepatide Claims

A dispute over weight-loss drug advertising highlights how patients should interpret comparisons between semaglutide and tirzepatide.
Swimming Program Reduces Disability From Chronic Low Back Pain in Clinical Trial

A clinical trial suggests structured swimming can reduce chronic low back pain disability, offering a low-impact treatment option.
Generic Oseltamivir FDA Approval Expands Influenza Treatment Options

Alembic Pharma’s generic oseltamivir approval may expand access to an established antiviral treatment for influenza.
Glioblastoma Nanoparticle Therapy: Why Promising Mouse Results Still Need Human Trials

A sugar-coated nanoparticle therapy improved survival in mice with glioblastoma, but safety and human trials remain essential.
Eight-Hour Intermittent Fasting May Help Sustain Weight Loss for a Year

A 12-week, eight-hour eating-window program showed lasting weight-loss benefits, but long-term success still depends on safety and adherence.
Why Innovative Medicine Access Differs Across Major Markets

Research examines why approval and access to innovative medicines vary across the United States, Europe, China and Japan.
Oral Solid Dosage Drugs Remain Central to New Medicine Approvals

Why tablets and capsules remain important in new drug approvals—and how formulation affects safety, effectiveness and access.
Gut Bacterial Toxin Discovery Reveals a New Colorectal Cancer Pathway

Researchers identify how a gut bacterial toxin uses claudin-4 to damage the colon, revealing a potential colorectal cancer prevention target.
Sugar-Coated Nanoparticles Target Glioblastoma Across the Blood-Brain Barrier

Sugar-coated nanoparticles improved survival in mice with glioblastoma by delivering genetic instructions across the blood-brain barrier.
Employer GLP-1 Coverage Gaps Put Weight-Loss Treatment Access at Risk

Employers are turning to savings accounts and nutrition programs as the cost of GLP-1 weight-loss drug coverage reshapes health benefits.
Medication Gadgets for Older Adults: Usability Study Tests Safer Treatment Support

A study testing 13 medication gadgets examines how usability could improve treatment support and reduce errors among older adults.
Pediatric Dose-Finding: Why Children Need More Than Smaller Adult Doses

Japan's pediatric drug initiative highlights why child-specific dosing, formulations and global clinical trials are essential for safer medicines.
ASCO Cancer Advances Highlight New Paths for Pancreatic, Head and Neck, and Bladder Treatment

ASCO research highlights emerging treatment strategies for pancreatic, head and neck, and bladder cancers—and the evidence still needed.
Ketogenic Diet and Small-Intestine Cancer Risk: What New Research Means

New research raises questions about ketogenic diets and small-intestine cancer risk, but the findings do not yet prove harm in people.
Weight-Loss Medicines Often Lack Proof of Better Quality of Life or Heart Outcomes

Weight loss alone may not improve daily life or heart health. Learn why drug-specific clinical outcomes matter when choosing obesity treatment.
Drug Metabolism AI Shows Better Data May Beat Bigger Models

A drug metabolism AI competition suggests high-quality training data may matter more than model size in pharmaceutical research.
Two-Isotope Imaging Could Personalize Alpha Therapy for Metastatic Prostate Cancer

Researchers are exploring two-isotope imaging to personalize targeted alpha therapy for metastatic prostate cancer.
Insulin Knowledge May Shape Treatment Success in Type 2 Diabetes

Research examines how insulin knowledge, attitudes and daily practices may influence treatment success in type 2 diabetes.
Brain Cancer Vaccine Approval Delay Raises Regulatory Transparency Questions

A prolonged UK review of an experimental glioblastoma vaccine highlights questions about evidence, transparency and regulatory timelines.
Weight-Loss Drug Popularity Grows as Access Barriers Limit GLP-1 Treatment

GLP-1 weight-loss drugs are increasingly familiar, but cost, coverage, eligibility and side effects continue to limit treatment access.
Who Qualifies for GLP-1 Weight-Loss Drugs—and Why Use Remains Limited

GLP-1 weight-loss drugs are increasingly popular, but eligibility, cost, side effects and long-term treatment needs still limit use.
Fasting and the Gut Microbiome: Research Explores Protection From Radiation Injury

Early research suggests short-term fasting may help gut microbes support intestinal recovery after radiation treatment.
Focused Ultrasound for Twin-Twin Transfusion Syndrome: A New Non-Invasive Treatment Approach

Early research explores whether focused ultrasound could offer a non-invasive treatment option for twin-twin transfusion syndrome.
GLP-1 Weight-Loss Medicines and Weight Regain: How to Plan for Long-Term Care

Why weight can return after GLP-1 medicines stop, and how patients can plan safer long-term obesity care with clinicians.
Wearable Injector for Multiple Myeloma Treatment: FDA Clearance Explained

The FDA has cleared a wearable injector form of Sanofi's multiple myeloma medicine, offering a new treatment delivery option.
Intermittent Fasting vs Calorie Counting: Which Weight-Loss Approach Is Easier to Sustain?

New research suggests intermittent fasting may match calorie counting for weight loss while feeling easier for some adults.
Yeast Beta-Glucan Supplement May Support Cancer Immunity

New research suggests a yeast-derived supplement may help strengthen immune cells involved in cancer defense.
Long COVID Fatigue Drugs Show Limited Benefit in Early Trial

A trial of repurposed medicines for long COVID fatigue found only modest short-term improvement, underscoring the need for better treatments.
GLP-1 Weight-Loss Drugs and Medicare: Safety Monitoring for Older Adults

Medicare’s new weight-loss drug coverage may widen GLP-1 access, but older adults need careful monitoring for safety and muscle loss.
GLP-1 Longevity Claims: What Heart and Kidney Trial Evidence Shows

GLP-1 drugs are being discussed as longevity medicines, but trial evidence currently points to heart, kidney, and metabolic benefits.
Medicare GLP-1 Bridge Program Expands Access to Obesity Medicines

Medicare's GLP-1 Bridge pilot lowers costs for eligible obesity medicines, raising access, safety and long-term coverage questions.
Inulin Propionate Ester Weight Control Additive Gains EU Novel Food Clearance

EU clearance for inulin propionate ester spotlights a fiber-based additive that may support satiety and weight-gain prevention.
Novel Fiber Additives for Weight Management and Metabolic Health

New interest in gut-derived fiber additives highlights a food-based approach to weight management and metabolic health.
FDA Peptide Compounding Review Raises Questions for Longevity Medicine

FDA peptide compounding review highlights safety, evidence and access questions for wellness and longevity treatments.
Medicare GLP-1 Coverage for Weight Loss: What Patients Should Know

Medicare's GLP-1 pilot could lower costs for eligible older adults using obesity drugs, but clinical monitoring remains essential.
Vitamin B12 Targeted Therapy for Glioblastoma Shows Early Brain Cancer Promise

A vitamin B12-based compound may help deliver treatment across the blood-brain barrier to glioblastoma tumors, early research suggests.
Tegoprubart Trial Points to a New Path for Kidney Transplant Rejection Prevention

An experimental anti-CD40L antibody could reduce reliance on tacrolimus after kidney transplant, pending larger safety data.
Continuous Manufacturing Drug Approvals Signal a New Medicine Supply Model

FDA-linked continuous manufacturing approvals are rising, with potential benefits for drug quality and medicine supply resilience.
Model-Informed Pediatric Dosing: A Faster Path to Child-Safe Medicines

Regulators are using pediatric pharmacology, trial design and age-appropriate formulations to close child medicine evidence gaps.
Pregnancy Drug Labeling: FDA and EMA Differences Shape Safer Prescribing

FDA and EMA pregnancy and lactation drug labels can differ, shaping safer prescribing before conception, pregnancy and breastfeeding.
Plerixafor and Immunotherapy: FDA-Approved Drug Shows Rare Liver Cancer Signal

FDA-approved plerixafor may help checkpoint therapy reach rare liver cancer by disrupting CXCR4 immune-cell trapping.
Early-Onset Cancer Risk: Biological Aging Signals May Help Explain Rising Diagnoses

New research examines whether faster biological aging may help explain rising cancer diagnoses in adults under 50.
Light-Based Thyroid Cancer Imaging Could Improve Nodule Diagnosis

New optical imaging research may help doctors distinguish thyroid cancer from benign nodules and reduce avoidable surgery.
Braftovi Encorafenib Moves Earlier in BRAF-Mutated Colorectal Cancer Treatment

Europe expands Braftovi use in BRAF V600E metastatic colorectal cancer, moving targeted therapy earlier in treatment.
Semaglutide Generics Could Change Access to Obesity Treatment Worldwide

Lower-cost semaglutide versions could expand obesity treatment access, but quality, prescribing and follow-up remain critical.
EMA Medicine Review Adds New Cancer and Infectious Disease Treatment Options

EMA-linked drug recommendations highlight new cancer therapies and combination vaccine strategies for European patients.
SCD1 and Cancer Treatment Resistance: Lipid Metabolism Emerges as a Therapeutic Target

New cancer metabolism research highlights SCD1, a lipid enzyme that may help tumors survive treatment pressure.
GLP-1 Weight-Loss Drugs and Male Fertility: New Research Points to Sperm Health Signals

New GLP-1 research suggests obesity treatment may improve male fertility markers, but the drugs are not fertility therapy.
Vitamin B3 and Glioblastoma: High-Dose Niacin Trial Tests Brain Cancer Immune Strategy

A clinical trial is testing whether high-dose vitamin B3 may support immune activity in glioblastoma treatment.
Genicular Artery Embolization for Knee Arthritis: Pain Relief Without Joint Surgery

A minimally invasive artery-blocking procedure may reduce knee osteoarthritis pain for selected patients without joint surgery.
Lunsumio-Polivy FDA Review: Targeted Lymphoma Combination Moves Forward

FDA review of Roche's Lunsumio-Polivy combo may expand targeted lymphoma treatment with a bispecific antibody and antibody-drug conjugate.
Amylin and GLP-1 Diabetes Therapy: Why Dual Hormone Treatment Is Drawing Attention

Dual amylin and GLP-1 therapies may reshape type 2 diabetes care by targeting appetite, weight and blood sugar together.
Epigenetic Age Tests and Weight-Loss Drugs: What the Biomarker Signal Means

New GLP-1 aging research raises a practical question: what do epigenetic age tests actually tell patients and clinicians?
Semaglutide and Bone Fracture Risk: Diabetes Study Signals Possible Added Protection

A real-world study links semaglutide with fewer fractures in type 2 diabetes despite weight loss, raising new questions about bone safety.
GLP-1 Medicines and Aging Biomarkers: What Metabolic Health Can and Cannot Tell Us

New GLP-1 aging biomarker research raises promise and caution about weight loss drugs, metabolism and healthy aging.
Opioid Vaccine Science: Antibody Strategy Targets Fentanyl Before It Reaches the Brain

Experimental fentanyl vaccine research uses antibodies to block the drug before it reaches the brain, but clinical proof is still needed.
Retatrutide for Type 2 Diabetes: Triple-Agonist Injection Targets Blood Sugar and Weight

Retatrutide may improve type 2 diabetes care by lowering HbA1c and body weight, but safety and access questions remain.
Triple-Agonist Obesity Medicines May Narrow the Gap With Bariatric Surgery

Retatrutide results highlight how next-generation incretin drugs may change obesity treatment and bariatric surgery decisions.
Retatrutide Phase 3 Trial: Triple-Agonist Obesity Drug Shows Surgery-Level Weight Loss

Retatrutide, an investigational triple-agonist obesity drug, produced major weight loss in phase 3 trial results.
Avalyn Pharma FDA Watch: Inhaled Antifibrotic Drugs for Pulmonary Fibrosis

Avalyn Pharma’s FDA watch highlights inhaled antifibrotic drug development for pulmonary fibrosis and future approval milestones.
Advanced Brain Tumor Imaging: MRI, PET and Precision Treatment Planning

Advanced MRI and PET imaging are changing brain tumor diagnosis, surgery planning and treatment monitoring.
Semaglutide and Biological Aging: What New GLP-1 Research May Mean

New GLP-1 research suggests semaglutide may influence biological aging markers, but clinical meaning remains uncertain.
Knee Osteoarthritis Pain Relief: Minimally Invasive Blood Vessel Treatment Shows Promise

A minimally invasive procedure for knee osteoarthritis may reduce pain by targeting abnormal blood vessels linked to inflammation.
Tzield for Newly Diagnosed Type 1 Diabetes: FDA Expands Pediatric Immunotherapy

FDA approval expands Tzield use in children and teens with newly diagnosed type 1 diabetes to help preserve insulin production.
Obesity Medicine and Fitness Monitoring: Protecting Movement During Weight-Loss Treatment

New activity-tracking research highlights why exercise, muscle preservation and monitoring matter during obesity drug treatment.
Drug-Loaded Nanofibers for Brain Cancer Treatment: A New Local Therapy Strategy

Drug-filled nanofibers may offer a new way to deliver brain cancer treatment directly after tumor surgery.
GLP-1 Weight-Loss Drugs and Exercise: Why Movement Plans Matter

New activity data raise a practical question: should GLP-1 weight-loss treatment include a structured exercise plan?
Thyroid Cancer Risk and Hormone Exposure: What New Endocrine Research Suggests

New endocrine research links longer female hormone exposure with thyroid cancer risk, raising questions for hormone therapy counseling.
GLP-1 Weight-Loss Drugs and Physical Activity: Why Step Counts Matter

New Fitbit-based research suggests people using GLP-1 weight-loss drugs may move less as weight falls.
Retatrutide Safety Warning: Unapproved Triple-Agonist Weight-Loss Drug Raises Concern

Retatrutide is drawing attention for major weight-loss results, but FDA warnings highlight risks from unapproved versions.
Body Clock and Cancer Risk: Why Treatment Timing May Matter

Circadian clock research links sleep-wake timing, inflammation and cancer biology, raising questions about prevention and treatment timing.
Sugary Drinks and Liver Cancer Risk: What New Research Means

New cohort findings link sugary drinks with higher liver cancer risk. Learn what the evidence means and how to reduce risk.
Weight-Loss Treatment and Cancer Risk in Adults Without Diabetes

New research links obesity treatment with lower obesity-related cancer risk in adults without diabetes, but causality remains unproven.
Repurposed Immune Drug May Improve Blood Sugar in Type 1 Diabetes

A repurposed immune drug may reprogram white blood cells in type 1 diabetes, raising hopes for beta-cell preservation beyond insulin.
Exilby Authorization Highlights Non-Opioid Chronic Low Back Pain Treatment

Exilby’s European authorization highlights a non-opioid drug approach for chronic low back pain as U.S. Phase 3 testing continues.
Dasatinib-Quercetin Brain Safety Signal Raises Caution for Anti-Aging Senolytics

A mouse study links dasatinib-quercetin senolytic therapy to myelin loss, raising safety questions for anti-aging use.
Weight Regain and Metabolism: Research Challenges Diet Damage Fears

New research challenges the idea that weight regain permanently damages metabolism after dieting.
Xocova COVID Prevention Pill: FDA Approval Expands Post-Exposure Protection

FDA approval of Xocova adds an oral COVID-19 post-exposure prevention option for adults and adolescents after close contact.
ASCO Cancer Breakthroughs Signal Shift Toward Organ-Sparing Precision Oncology

ASCO cancer updates highlight precision drugs, immune treatments and organ-sparing care that may change oncology practice.
CagriSema Diabetes Trial: Amylin-GLP-1 Combination Lowers Blood Sugar and Weight

CagriSema combines cagrilintide and semaglutide, showing stronger glucose and weight effects in type 2 diabetes trials.
Aleniglipron GLP-1 Pill Shows Phase 2 Weight-Loss Results in Obesity Trial

Oral aleniglipron showed meaningful phase 2b weight loss in adults with obesity, but larger phase 3 safety data are still needed.
Oral GLP-1 Drugs Could Reshape Weight-Loss Treatment Access

A phase 2b aleniglipron trial adds evidence for pill-based GLP-1 obesity care, raising questions about access, safety and outcomes.
SGLT2 Inhibitor Ketosis Risk: New Clues for Safer Diabetes Treatment

Empagliflozin metabolism research renews focus on ketone monitoring, sick-day rules and safer SGLT2 inhibitor use in diabetes.
Intermittent Fasting After 60: Benefits, Muscle Loss Risks and Safer Weight Loss

Intermittent fasting after 60 may help some people reduce calories, but experts warn about muscle loss, hypoglycemia and medication risks.
GLP-1 Drugs and Knee Osteoarthritis: Could Weight-Loss Medicine Delay Joint Replacement?

New observational research examines whether GLP-1 medicines may reduce knee replacement risk in osteoarthritis.
Pancreatic Cancer Clinical Trials Expand New Drug Treatment Options

Pancreatic cancer trials are testing drug combinations, KRAS-targeted therapy and precision treatment strategies for selected patients.
Oral Add-On Treatment for Type 1 Diabetes: Benefits and Ketoacidosis Risks

Oral add-ons to insulin may improve glucose control in type 1 diabetes, but ketone monitoring and DKA risk remain central.
AI Drug Discovery Targets New Cardiometabolic Therapies

Insilico and Qilu's near-$120 million AI drug discovery deal highlights a new push for cardiometabolic treatments.
Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer

New oncology research highlights when selected bladder cancer patients may avoid bladder-removal surgery.
AI-Enabled Cardiometabolic Drug Development Gains Pharma Momentum

Insilico and Qilu's near $120 million collaboration highlights AI's growing role in cardiometabolic drug discovery.
AI Sepsis Prediction Models Need Stronger Validation Before Guiding Antibiotic Treatment

New concerns over time bias in AI sepsis models highlight risks for antibiotic timing, overtreatment and clinical safety.
Generic Heart Drug Labeling Ruling Could Shape Cardiovascular Medicine Access

A Supreme Court ruling on generic Vascepa highlights how skinny labels may affect competition and heart drug access.
Calcium Channel Blockers and Kidney Risk in Type 2 Diabetes

New kidney safety data raise questions about calcium channel blockers in type 2 diabetes and how doctors choose blood pressure drugs.
Obesity Medicines and Cancer Prevention: What GLP-1 Research Suggests

Large studies link GLP-1 obesity medicines with lower risk of some obesity-related cancers, but experts caution they are not cancer drugs.
Semaglutide Trial Finds Slower Epigenetic Aging Signals in Adults With HIV

Semaglutide was linked to slower DNA methylation aging markers in a randomized trial of adults with HIV-associated lipohypertrophy.
Type 1 Diabetes Cell Therapy: Islet Replacement Moves Toward Treatment Reality

Stem-cell islet therapy is advancing for type 1 diabetes, but safety, durability and access remain key questions.
Insulin Access in Diabetes Care: Why a Century-Old Treatment Remains Out of Reach

Insulin is essential for diabetes care, yet cost, supply chains and health-system gaps still limit access for millions worldwide.
Obesity Drug Pipeline Expands Beyond Weight Loss Into Metabolic Disease

New obesity medicines are being developed for heart, liver and metabolic disease as GLP-1 therapy moves beyond weight loss.
Amivantamab Injection Shows Promise for Resistant Head and Neck Cancer

Amivantamab showed tumor responses in advanced head and neck cancer after chemotherapy and immunotherapy, but approval questions remain.
Empagliflozin Ketosis Research Points to Anaplerotic Strategy for SGLT2 Inhibitor Safety

Research suggests anaplerotic therapy may counter empagliflozin-related ketosis, a rare SGLT2 inhibitor safety concern.
PGDHi Muscle-Repair Drug May Protect Strength During GLP-1 Weight Loss

Mouse research suggests a 15-PGDH inhibitor may improve muscle repair during semaglutide weight loss without blunting fat loss.
Daraxonrasib Pancreatic Cancer Trial: RAS Inhibitor Nearly Doubles Survival

A phase 3 trial found oral daraxonrasib improved survival versus chemotherapy in previously treated metastatic pancreatic cancer.
GLP-1 Weight-Loss Drugs and Breast Cancer Risk: What the Evidence Suggests

New findings suggest GLP-1 weight-loss drugs may be linked to lower breast cancer risk, but proof of prevention is not yet established.
Insomnia and Cancer Risk: Why Sleep Health Is Entering Oncology Research

ASCO-linked cancer research highlights insomnia as a growing focus in prevention, survivorship and oncology care.
Zepbound Coverage Restored: What It Means for Weight-Loss Drug Access

CVS coverage reversal for Zepbound highlights how insurance decisions shape access to GLP-1 weight-loss treatment.
Cancer Vaccine Research Targets Immune-Cold Tumors and Checkpoint Resistance

Research links 9p21 immune gene loss to checkpoint resistance and points to dendritic cell vaccine strategies.
Oncolytic Virus Cancer Immunotherapy Faces New FDA Scrutiny

FDA review of oncolytic virus therapy highlights promise and uncertainty in cancer immunotherapy for melanoma.
Counterfeit GLP-1 Weight-Loss Drugs Raise Online Pharmacy Safety Concerns

EMA warnings over illegal GLP-1 weight-loss drugs highlight risks from counterfeit online semaglutide and tirzepatide products.
China-Origin Cancer Drugs Are Reshaping the Global Oncology Pipeline

China-origin cancer medicines are increasingly entering global trials and licensing deals, changing oncology drug development.
Breakthrough Drug Approvals and Safety: Why REMS May Matter More Than Boxed Warnings

New research links FDA breakthrough therapy approvals with higher postmarket safety reports and highlights REMS as a key safeguard.
Metformin and Healthy Aging: Why a Diabetes Drug Is Reshaping Cancer Research

New metformin research highlights how a common diabetes drug may influence aging biology and cancer pathways beyond blood sugar control.
Personalized Insulin Response: Why A1C Reduction Varies in Diabetes Care

Why insulin lowers A1C differently from patient to patient, and what personalized diabetes care means for safer blood sugar control.
Semaglutide After Bariatric Surgery: Trial Shows New Option for Poor Weight Loss

A randomized trial suggests semaglutide 2.4 mg may help patients with poor weight loss after bariatric surgery.
GLP-1 Nutrition Care: Protecting Muscle and Micronutrients During Weight-Loss Treatment

GLP-1 and GIP/GLP-1 drugs can reduce appetite sharply, making nutrition planning essential during obesity treatment.
Cancer Survivorship Lifestyle Habits: Diet, Exercise and Heart Health Linked to Longer Life

New evidence links healthy diet, activity, weight and heart-health habits with longer survival after cancer diagnosis.
Phone-Based Weight Loss Program May Support Breast Cancer Recovery

A phone-based weight loss program may help breast cancer patients improve weight, diet and activity during recovery.
Real-World Data in Medicine Safety Monitoring: How Regulators Are Changing Drug Reviews

Regulators are expanding real-world data use to monitor medicine safety, speed reviews, and improve public health surveillance.
Machine Learning for Pregnancy Drug Safety: AI Tools Target a Major Evidence Gap

AI and real-world data may help clarify medication risks in pregnancy, but experts say models need careful validation.
Semaglutide for Alcohol Use Disorder and Obesity: What New Research Suggests

New research suggests semaglutide may reduce heavy drinking while supporting weight loss in adults with alcohol use disorder and obesity.
Senolytic Drug Combo Raises Brain Myelin Safety Concerns in Mouse Study

Mouse research links dasatinib plus quercetin senolytic therapy to myelin damage, raising caution for anti-aging use.
GLP-1 Weight-Loss Drugs and Inflammatory Bowel Disease Safety

What patients with Crohn's disease or ulcerative colitis should know about GLP-1 weight-loss drugs, gut symptoms, and IBD care.
EMA Data and AI Strategy Targets Faster, Safer Medicine Reviews

EMA's data and AI strategy could reshape medicine reviews, real-world evidence, and drug safety monitoring across Europe.
Brain-Targeted Obesity Drugs: How Appetite Pathways Are Changing Weight-Loss Treatment

New GLP-1 research is sharpening interest in brain appetite circuits and next-generation obesity medicines.
GLP-1 Weight-Loss Drugs: Brain Cell Pathway May Explain Appetite Control

New GLP-1 research highlights how brain cell signaling may help explain appetite reduction and sustained weight loss.
Ceramide Metabolism May Help Predict Prostate Cancer Drug Response

Research links ceramide lipid patterns with response to androgen receptor inhibitors in advanced prostate cancer.
Didgeridoo Breathing Training for Sleep Apnea: What the Evidence Shows

A BMJ randomized trial highlights how didgeridoo breathing training may help some adults with obstructive sleep apnea.
Ovarian Cancer Immune Memory Cells May Point to Vaccine Strategies

New ovarian cancer research suggests memory B cells may produce tumor-targeting antibodies, raising cautious hope for vaccine development.
CAR T-Cell Therapy for Autoimmune Disease: Cancer Immunotherapy Enters Lupus Trials

Cancer CAR T therapy is being tested for lupus and other autoimmune diseases, offering hope for immune reset but requiring trials.
Inqovi Plus Venetoclax for Acute Myeloid Leukemia: What the FDA Approval Means

FDA approval of Inqovi plus venetoclax adds an oral hypomethylating option for some adults with newly diagnosed AML.
Bariatric Surgery and Cancer Risk: Insulin, Sex and FTO Genetics Offer New Clues

Long-term Swedish data suggest bariatric surgery may lower some cancer risks, especially in women with high insulin.
New Drug Approvals to Watch: What Patients Should Know

A practical look at high-impact drug approvals expected to shape treatment access, FDA review, and patient care.
FDA Regulatory Instability May Slow Access to New Medicines

FDA staffing and review delays may affect drug approvals, trial timelines, and patient access to new therapies.
Personalized Gait Retraining May Ease Knee Osteoarthritis Pain and Slow Cartilage Damage

A personalized walking-angle program may reduce knee osteoarthritis pain and cartilage stress without drugs or surgery.
Topical Senolytic ABT-263 May Speed Wound Healing in Aging Skin

ABT-263, a topical senolytic drug, improved wound repair in aged mouse skin by clearing senescent cells.
FDA Drug Review Delays Raise Concerns for Patient Access to New Treatments

Regulatory delays at the FDA could affect drug approvals, clinical trials, and patient access to new medicines.
Insulin Therapy for Diabetes: Safe Use, Dosing, and Modern Treatment Options

How insulin therapy works for diabetes, including safe use, dosing principles, hypoglycemia prevention, and modern delivery options.
Microbiome Therapy for Graft-Versus-Host Disease Faces European Re-Review

MaaT Pharma plans a European re-examination for its microbiome therapy for acute graft-versus-host disease.
Generic GLP-1 Weight-Loss Drugs Face India Regulatory Scrutiny

Indian drugmakers are racing into generic GLP-1 weight-loss medicines as regulators weigh quality, safety, and access.
Cell Sugar Patterns Could Open New Path for Early Cancer Detection

New glycan imaging research suggests cell-surface sugar patterns may help detect cancer earlier and more precisely.
Retatrutide Weight Loss Drug: Triple-Hormone Therapy Shows Bariatric-Level Results

Retatrutide, an investigational triple-hormone obesity drug, produced major weight loss in trials. What patients should know.
GLP-1 Drugs Like Ozempic Open New Treatment Path for Obstructive Sleep Apnea

GLP-1 receptor agonists such as semaglutide and tirzepatide are emerging as a viable treatment for obstructive sleep apnea by targeting obesity, the leading dri
How GLP-1 Drugs Like Ozempic Are Reshaping Sleep Apnea Treatment

GLP-1 receptor agonists like Ozempic may offer a new treatment path for obstructive sleep apnea by targeting weight loss and upper airway inflammation.
Tirzepatide for Sleep Apnea: Which Patients See the Greatest Improvement?

New research identifies which patients with obesity and obstructive sleep apnea benefit most from tirzepatide, the GLP-1/GIP agonist now FDA-approved for OSA.
Weight Loss Maintenance: Randomized Trial Tests Long-Term Strategies for Adults with Obesity

A new Nature Medicine randomized trial examines strategies to prevent weight regain after initial loss, addressing one of obesity medicine's hardest problems.
GLP-1 Weight-Loss Drugs Linked to Lower Death and Recurrence Risk After Breast Cancer

New JAMA Network Open research finds GLP-1 receptor agonists like semaglutide may improve survival and reduce recurrence in breast cancer patients with obesity
Yo-Yo Dieting Reconsidered: New Analysis Challenges Weight Cycling Harm Assumptions

A new comprehensive analysis questions whether weight cycling is truly more harmful than sustained obesity. Here's what the research actually shows.
GLP-1 Drugs and Muscle Loss: New Research Finds Effects Mirror Conventional Weight Loss

New research from the Lifespan Research Institute suggests GLP-1 medications like semaglutide cause muscle loss similar to traditional weight loss, easing conce
Resmetirom for MASH: How the First Approved Fatty Liver Drug Is Reshaping Hepatology Care

Resmetirom (Rezdiffra), the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis, is changing hepatology practice as access expands
India's CDSCO Seeks Public Input on Drug Approval Reforms to Level Regulatory Playing Field

India's drug regulator CDSCO opens public consultation on harmonizing drug approval pathways, aiming to align domestic and foreign manufacturers under unified s
Personalized mRNA Vaccine Shows Promise Against Glioblastoma in Early Trial

A personalized vaccine targeting glioblastoma elicited robust immune responses in early trials, offering new hope against one of the deadliest brain cancers.
8,500 Steps a Day Helps Dieters Keep Weight Off, Research Suggests

New research suggests walking around 8,500 steps daily may help people who have lost weight successfully maintain their results long-term.
Oral Orforglipron Cuts Weight and Blood Sugar in Older Adults, Trial Finds

New trial data show daily oral orforglipron meaningfully reduces body weight and improves glycemic control in seniors with type 2 diabetes.
Walking 8,500 Steps Daily May Prevent Weight Regain After Dieting, Analysis Finds

New international analysis suggests walking approximately 8,500 steps daily may help prevent weight regain after successful dieting, offering a simple maintenan
Pancreatic Cancer Treatment Advance: New Approach Targets One of Medicine's Deadliest Diseases

Researchers report a potential breakthrough in pancreatic cancer treatment, one of the most lethal cancers with historically poor survival outcomes.
Personalised mRNA Vaccines Enter Trial for Children With Deadly Brain Cancers

Australian researchers launch a world-first trial of personalised mRNA vaccines targeting pediatric high-grade gliomas, including DIPG, using each child's tumou
Why GLP-1 Weight-Loss Injections Are Not a Quick Fix: Experts Urge Caution

Experts warn GLP-1 weight-loss injections like semaglutide and tirzepatide require lifestyle changes, carry side effects, and are not a shortcut to lasting weig
Type 1 Diabetes Blood Sugar Management: What the Evidence Says About Supplements

Insulin remains the cornerstone of type 1 diabetes care. A new review examines which supplements show evidence and which fall short.
mRNA Cancer Vaccines: Promise of Personalized Treatment Faces Misinformation Headwinds

mRNA cancer vaccines show transformative potential for treatment and prevention, but vaccine misinformation threatens clinical progress and patient access.
FDA Issues Final Guidance on Pregnancy Safety Studies for Approved Drugs

FDA finalizes guidance for postapproval pregnancy safety studies, recommending stronger methodologies to protect pregnant patients prescribed drugs and biologic
Morning Checkpoint Inhibitor Doses Linked to Better Liver Cancer Outcomes

New research suggests time-of-day matters for immunotherapy in hepatocellular carcinoma, with morning dosing associated with stronger immune responses and bette
Short Pembrolizumab Course Before Surgery Keeps MMR-Deficient Colon Cancer Patients Disease-Free

A UK-led trial shows nine weeks of pembrolizumab before surgery delivered durable remission in patients with mismatch repair deficient colorectal cancer.
Global Drug Access Gap: Why New Therapies Reach Patients Years Apart

New analysis reveals stark disparities in how quickly innovative therapies reach patients in the US, EU, China, and Japan, with delays of several years for some
Hip Replacement Outperforms Exercise Therapy Alone for Moderate-to-Severe Osteoarthritis

A landmark yearlong randomized trial finds total hip arthroplasty delivers significantly better pain relief and function than exercise-only care in moderate-to-
FDA Accelerated Approval Faces Transparency Crisis as Researchers Demand Evidence Reform

Research firm analysis reveals critical transparency gaps in FDA's accelerated approval pathway, prompting calls for stricter post-market evidence requirements.
FDA Grants Expanded Access to Promising Pancreatic Cancer Drug Ahead of Approval

FDA grants early access to an investigational pancreatic cancer drug, allowing patients with advanced disease to receive treatment before formal approval.
Immunotherapy Trial Leaves Bowel Cancer Patients Disease-Free for Nearly Three Years

A landmark immunotherapy trial shows patients with mismatch repair-deficient bowel cancer remain cancer-free up to three years after treatment with checkpoint i
FDA Advisors Back AstraZeneca's Truqap Combo for PTEN-Deficient Prostate Cancer

FDA advisory committee supports AstraZeneca's Truqap (capivasertib) plus abiraterone for metastatic prostate cancer patients with PTEN loss, signaling a precisi
GLP-1 Drugs and Body Positivity: How Ozempic Is Reshaping Weight Stigma

GLP-1 drugs like Ozempic and Mounjaro are transforming weight loss medicine and challenging the body positivity movement. Experts weigh in on the cultural shift
States Move to Drop GLP-1 Weight Loss Drugs From Medicaid Amid Soaring Costs

A growing number of US states are reconsidering Medicaid coverage of GLP-1 obesity drugs like Wegovy and Zepbound as budget pressures mount.
FDA Approves Self-Administered Saphnelo for Systemic Lupus Erythematosus

FDA approves AstraZeneca's Saphnelo (anifrolumab) for at-home self-administration in adults with moderate to severe systemic lupus erythematosus.
Osteoarthritis Symptom Relief: Evidence-Based Treatments and Emerging Therapies

Discover proven osteoarthritis treatments that ease joint pain and stiffness, plus emerging therapies reshaping the future of OA care.
FDA Moves to Restrict Mass Compounding of GLP-1 Weight-Loss Drugs

FDA proposes new restrictions on mass-compounded versions of semaglutide and tirzepatide, citing patient safety concerns as branded GLP-1 supply stabilizes.
GLP-1 Drugs Linked to Fewer Asthma Flare-Ups in Overweight Patients

New research suggests GLP-1 receptor agonists like semaglutide may reduce asthma exacerbations in adults with overweight or obesity, pointing to anti-inflammato
GLP-1 Drugs for Lifelong Use: Patient Benefits, Risks, and Clinical Realities

Patients on GLP-1 drugs like Ozempic and Wegovy report rapid weight loss alongside cardiovascular and metabolic benefits, but long-term use raises questions.
FDA Grants Orphan Drug Designation to Pegrizeprument for Heart Transplant Rejection

FDA awards Orphan Drug Designation to pegrizeprument, an investigational therapy aimed at preventing acute rejection in heart transplant recipients.
Aerobic Exercise Tops All Workouts for Knee Arthritis Pain, Major Review Finds

A sweeping analysis of 217 trials concludes aerobic exercise like walking, cycling and swimming delivers the greatest pain relief for knee osteoarthritis.
Biohaven Targets Muscle Preservation in Obesity Treatment Race

While GLP-1 drugs dominate weight loss, Biohaven pursues muscle-preserving therapies to address sarcopenia risk in obesity treatment.
Pausing and Restarting GLP-1 Weight Loss Drugs May Blunt Their Effectiveness

New research suggests stopping and restarting GLP-1 medications like semaglutide and tirzepatide for weight loss may reduce their long-term effectiveness.
FDA Moves to Block Compounded GLP-1 Drugs: Semaglutide and Tirzepatide Face 503B Exclusion

FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, ending compounding of these blockbuster GLP-1 weight loss drugs.
mRNA Vaccine Clinical Trials Surge: Global Landscape Analysis Reveals Pipeline Beyond COVID-19

A systematic analysis of ClinicalTrials.gov reveals the global mRNA vaccine pipeline has expanded far beyond COVID-19 into oncology, infectious disease, and rar
IBD Immunosuppressants Show No Increased Heart Attack Risk in Large Medicare Analysis

New Medicare analysis finds no elevated risk of heart attacks or strokes in inflammatory bowel disease patients taking immunosuppressant therapies.
Dextromethorphan-Bupropion Approved for Alzheimer's Agitation: How AXS-05 Targets NMDA and Sigma-1 Receptors

FDA clears Axsome's dextromethorphan-bupropion combination for Alzheimer's-related agitation, addressing a major unmet need with a non-antipsychotic mechanism.
Boehringer's Survodutide Achieves 16.6% Weight Loss in Obesity Trial

Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist survodutide showed 16.6% weight loss in phase 3 trials, intensifying competition in the obesity drug
Academic Research Drives FDA Approval of New Rare Genetic Disorder Drug

Academic-industry collaboration accelerates FDA approval of new therapies for rare genetic disorders, expanding treatment options for patients with limited alte
EULAR Urges Doctors to Prescribe Exercise as Core Arthritis Treatment

Updated EULAR guidelines call physical activity counseling an integral part of standard care for patients with rheumatic and musculoskeletal diseases.
GLP-1 Weight Loss Success Hinges on Nutrition Counseling, Dietitians Say

Registered dietitians say structured nutrition guidance is essential for safe, sustainable weight loss with GLP-1 medications like semaglutide and tirzepatide.
Psychotropic Drugs in Dementia: Half of Older Patients Stay on Medications a Year Later

New research finds half of dementia patients started on psychotropic drugs in hospitals or ERs remain on them a year later, raising deprescribing concerns.
FDA's New Drug Pricing Approach Adds Uncertainty to Approval Process

FDA's evolving consideration of drug pricing during approval reviews introduces new uncertainty for pharmaceutical companies and patient access.
Gut Reset Procedure May Prevent Weight Regain After Stopping Ozempic and Wegovy

A minimally invasive endoscopic gut procedure shows promise for helping patients maintain weight loss after discontinuing GLP-1 medications like semaglutide.
FDA Shifts to Single Pivotal Trial Standard for New Drug Approvals

FDA moves toward accepting one adequate well-controlled study to approve new drugs, aiming to speed access while raising questions about evidence quality.
FDA Single-Trial Drug Approval Pathway: Faster Access or Weakened Evidence?

FDA shifts toward requiring only one adequate study for new drug approvals, accelerating patient access while raising questions about post-market evidence.
FDA Approves First Gene Therapy for Genetic Hearing Loss: What Patients Need to Know

Regeneron's gene therapy becomes the first FDA-approved treatment to restore hearing in children with otoferlin-related genetic deafness through a single inject
Transdermal Insulin Skin Cream: Needle-Free Diabetes Treatment in Development

Researchers are developing a transdermal insulin cream that could deliver diabetes medication through the skin, potentially eliminating daily injections for mil
Repurposed Drugs Show Promise for Aggressive Infant Leukemia Treatment

Three clinically available drugs may transform treatment of MLL-rearranged infant leukemia, one of the deadliest childhood cancers, new research in HemaSphere s
Fezolinetant: Non-Hormonal Drug Targets Brain Pathway Behind Menopausal Hot Flashes

Fezolinetant offers women a non-hormonal option for moderate to severe hot flashes by blocking the NK3 receptor pathway in the brain's thermoregulatory center.
New Preeclampsia Treatment May Safely Extend Pregnancy in Severe Early Cases

A novel preeclampsia treatment from Cedars-Sinai may safely prolong pregnancy in women with severe early-onset disease, potentially reducing premature births.
Actinium-225 Alpha Therapy: Next-Generation Radiopharmaceuticals Target Resistant Prostate Cancer

Actinium-225 alpha-emitter therapy is emerging as a next-generation theranostic for prostate cancer patients who have progressed on lutetium-177 treatment.
FDA Single-Study Drug Approvals: What Post-Market Surveillance Means for Patient Safety

FDA's expanded use of single-study drug approvals could speed access to new medicines, but raises questions about confirmatory evidence and post-market safety m
Beyond OTOF: What's Next in the Gene Therapy Pipeline for Genetic Hearing Loss

With the first gene therapy for genetic hearing loss approved, researchers are advancing treatments targeting GJB2, STRC, and other deafness genes.
Ketogenic Diet May Outperform Low-Fat Diet for Type 2 Diabetes Remission

New evidence suggests very low-carbohydrate ketogenic diets may achieve higher rates of type 2 diabetes remission than traditional low-fat diets.
FDA Approves First Gene Therapy for Genetic Hearing Loss: How Otarmeni Restores Hearing

FDA approves Otarmeni, the first dual-AAV gene therapy for OTOF-related hereditary hearing loss, offering durable hearing restoration to children with DFNB9.
Pediatric Brain Cancer Breakthrough: New Drug Delivery Research Targets Deadly Childhood Tumors

Pharmacy researchers advance pediatric brain cancer treatment with novel drug delivery systems designed to cross the blood-brain barrier in children.
Implanted Nerve Stimulator for Sleep Apnea: New Trial Shows Safety and Efficacy

A randomized controlled trial finds proximal hypoglossal nerve stimulation safely reduces obstructive sleep apnea severity, offering hope for CPAP-intolerant pa
Extra Antibiotic Powder Fails to Reduce Infection Risk in Complex Fracture Surgery

New clinical trial finds that adding vancomycin powder during complex fracture surgery does not further reduce post-operative infection rates compared to standa
FDA Overhauls Approval Pathway to Accelerate Rare Disease Gene Therapies

FDA introduces streamlined approval framework for rare disease gene therapies, offering new hope for patients with ultra-rare genetic conditions lacking treatme
GLP-1 Weight Loss Drugs Show Promise as New Treatment for MASLD and MASH Liver Disease

Obesity drugs like semaglutide and tirzepatide are emerging as potential treatments for MASLD and MASH, the most common chronic liver diseases worldwide.
South Korea's Lecraza Wins FDA Approval: A Milestone for Asian Oncology Innovation

Lecraza (lazertinib) from South Korea's Yuhan secures FDA approval for EGFR-mutated lung cancer, marking a historic breakthrough for Korean pharma.
FDA Approves First Brain-Penetrating Enzyme Therapy for Hunter Syndrome

FDA approves Avlayah (tividenofusp alfa-eknm) as a first-of-its-kind enzyme replacement therapy targeting neurologic manifestations of Hunter syndrome (MPS II).
Lazertinib Plus Amivantamab: FDA Nod Marks South Korea's First Homegrown Cancer Drug Milestone

Lazertinib (Leclaza), developed by South Korea's Yuhan Corporation, earned FDA approval with amivantamab as a first-line EGFR-mutated lung cancer therapy.
Blood Test for Aggressive Brain Tumors: Early Glioblastoma Detection Could Cut Surgical Risk

Researchers at the University of Sussex report a blood test capable of early detection of glioblastoma, the most aggressive brain tumor, potentially reducing th
Personalized mRNA Pancreatic Cancer Vaccine Shows Durable Immune Response in Extended Follow-Up

Extended follow-up of autogene cevumeran, a personalized mRNA pancreatic cancer vaccine, shows durable T-cell responses linked to delayed recurrence in early tr
Nutrition During Cancer Treatment: Evidence-Based Diet Strategies for Managing Side Effects

Cancer treatment often causes nausea, taste changes, and appetite loss. Learn evidence-based nutrition strategies to maintain strength during chemotherapy and r
Semaglutide May Preserve Lean Muscle Better Than Tirzepatide in Weight Loss Trial

New comparative trial suggests Novo Nordisk's semaglutide preserves lean body mass more effectively than Eli Lilly's tirzepatide during weight loss.
Anti-Aging Drug Fails Human Trial: What the Setback Means for Longevity Research

A highly anticipated anti-aging drug has failed to meet primary endpoints in human clinical trials, reshaping the outlook for the longevity pharmaceutical field
Theranostics Explained: Integrated Centers Combine Diagnosis and Targeted Radiotherapy

Theranostics pairs molecular imaging with targeted radioligand therapy, offering precision cancer treatment. New integrated centers aim to expand patient access
Transdermal Estradiol for Menopausal Hot Flashes: What the Evidence Shows

Transdermal estradiol remains the most effective treatment for moderate to severe menopausal vasomotor symptoms, with a safety profile distinct from oral hormon
Pediatric Brain Cancer: UNC Pharmacy Team Advances Research Toward Treatment Breakthrough

UNC Chapel Hill pharmacy researchers pursue new treatment approaches for pediatric brain tumors, the leading cause of cancer death in children.
Buprenorphine for Opioid Addiction in Pregnancy: No Added Risk of ADHD or Autism in Children

New research confirms buprenorphine use during pregnancy for opioid addiction does not increase neurodevelopmental disorder risk in children, including ADHD and
How GLP-1 Drugs Are Reshaping Obesity and Diabetes Treatment in Managed Care

GLP-1 receptor agonists like semaglutide and tirzepatide are driving major growth in obesity and diabetes treatment, creating new challenges for managed care.
How FDA Price Considerations May Slow New Drug Development Pipelines

FDA's evolving stance on drug pricing during approval reviews raises concerns about delays in bringing new treatments to patients and chilling pharmaceutical R&
New Legislation Aims to Strengthen FDA Authority Over Dietary Supplements

Proposed legislation seeks to reaffirm and expand FDA regulatory authority over dietary supplements, addressing safety and labeling concerns.
Transdermal Drug Delivery for Biologics: How Skin-Based Treatments Could Transform Chronic Disease Care

New transdermal delivery technologies may allow large-molecule drugs like insulin to be absorbed through the skin, potentially replacing injections for millions
Metformin May Help People With Type 1 Diabetes Use Less Insulin, New Trial Finds

A new clinical trial suggests metformin, a cheap drug for type 2 diabetes, may reduce insulin requirements in people with type 1 diabetes.
FDA Requests Additional Safety Data on Lilly's Newly Approved Oral Weight-Loss Pill

FDA seeks post-approval safety data from Eli Lilly on its oral GLP-1 weight-loss pill, raising questions about long-term monitoring of new obesity medications.
FDA Approves Rare Kidney Disease Drug Despite Trial Missing Kidney Function Goal

FDA greenlights Travere's rare kidney disease drug after pivotal trial failed to show improvement in kidney function, reigniting debate over surrogate endpoints
FDA 2025 Drug Approvals: Volume Holds Steady But Therapeutic Value Falls Below Historical Average

Analysis of FDA 2025 novel drug approvals shows stable numbers but fewer first-in-class and breakthrough therapies compared to recent years.
Sleep Deprivation Disrupts Gut Microbiota and Worsens Colorectal Cancer Outcomes

New research links chronic sleep loss to gut microbiome disruption that may accelerate colorectal cancer progression via altered immune responses.
Weight Loss Drug Cuts Heart and Liver Disease Risk in Obesity Trial

New clinical trial results show GLP-1 weight loss medications significantly reduce cardiovascular and liver disease risk in adults with obesity.
FDA Approves Sparsentan as First-Ever Treatment for Focal Segmental Glomerulosclerosis

The FDA has approved sparsentan (Filspari) as the first treatment specifically indicated for FSGS, a rare kidney disease with no prior approved therapies.
Gestational Diabetes and Insulin Resistance: How Blood Sugar Regulation During Sleep Affects Outcomes

New insights into gestational diabetes insulin treatment and how nocturnal blood sugar regulation impacts insulin resistance and maternal-fetal outcomes.
GLP-1 Drugs for Weight Loss: How Semaglutide and Tirzepatide Are Reshaping Medicine

GLP-1 receptor agonists like semaglutide and tirzepatide are transforming weight loss treatment and showing benefits for heart, kidney, and liver disease.
GLP-1 Drugs May Improve Liver Health Independent of Weight Loss, New Research Suggests

New mouse study finds GLP-1 receptor agonists improve liver health through mechanisms beyond weight loss, offering hope for NAFLD treatment.
Menopause Drug Market Surges: New Nonhormonal Therapies Transform Treatment Options

The menopause drug market is experiencing unprecedented growth as new nonhormonal therapies like fezolinetant join HRT options, giving women more treatment choi
Topical Treatments for Rheumatoid Arthritis Joint Pain: What Works and What Doesn't

Evidence-based guide to topical treatments for rheumatoid arthritis joint pain, including NSAIDs, capsaicin, and emerging therapies.
Sulthiame for Sleep Apnea: Clinical Trial Shows Drug Reduces Night-Time Breathing Pauses

A clinical trial finds sulthiame, a carbonic anhydrase inhibitor, significantly reduces breathing pauses in obstructive sleep apnea patients unable to tolerate
GLP-1 Weight Loss and Side Effects Linked to Genetic Variations: What It Means for Patients

New research links genetic variations to how patients respond to GLP-1 receptor agonists, explaining differences in weight loss outcomes and side effects.
Probiotics May Boost GLP-1 Drug Effectiveness in Obesity Treatment, New Research Suggests

New research suggests probiotics could enhance the weight loss effects of GLP-1 receptor agonists like semaglutide by improving gut microbiome composition.
FDA Regulatory Reform: What New Accelerated Approval Changes Mean for Patients

FDA accelerated approval pathway faces major reforms. Learn how regulatory changes affect drug access, confirmatory trials, and patient safety.
23andMe Identifies Genetic Markers That May Predict GLP-1 Drug Response for Weight Loss

23andMe research identifies genetic variants linked to how patients respond to GLP-1 weight loss drugs like semaglutide, advancing pharmacogenomics.
Jaw Cramps and Hypoglycemia: The Overlooked Warning Sign in Type 2 Diabetes

Jaw cramps can signal dangerously low blood sugar in people with type 2 diabetes on insulin. Learn why this symptom occurs and how to manage hypoglycemia safely
GLP-1 Weight-Loss Drugs May Relieve Arthritis Pain: What Doctors Are Finding

Doctors report GLP-1 weight-loss medications like semaglutide may reduce arthritis pain through anti-inflammatory effects beyond weight reduction alone.
Human Insulin for Diabetes: Why Doctors Are Revisiting Regular R Insulin

Regular human insulin (R insulin) is gaining renewed attention for diabetes management. Learn why some physicians advocate for its use alongside modern analogs.
Inhaled RNA Therapy Shows Promise for Reducing Lung Inflammation After Severe Infections

New inhaled RNA-based treatment reduces lung inflammation in preclinical models, offering hope for post-infection respiratory damage.
Weight Regain After Stopping Obesity Medication: What the Evidence Shows

A BMJ systematic review reveals how much weight people regain after discontinuing weight management medications like GLP-1 receptor agonists.
FDA Food and Dietary Supplement Labeling: What Health Claims Are Actually Allowed?

Understanding FDA regulation of health claims on food and dietary supplement labels, including the difference between approved and unauthorized claims.
FDA's New Drug Pricing Role: How Cost Considerations Could Reshape Approvals

The FDA's expanding role in drug pricing adds new uncertainty to the approval process. What this means for pharmaceutical companies and patients.
GLP-1 Weight-Loss Drug Side Effects: What Is 'Ozempic Face' and How to Manage It

GLP-1 drugs like semaglutide cause side effects beyond nausea. Learn about 'Ozempic face,' muscle loss, and how to reduce risks during treatment.
Genetic Variants in 1 in 10 People May Blunt GLP-1 Drug Response for Diabetes

New research finds common genetic variants may reduce how well GLP-1 receptor agonists lower blood sugar, pointing toward pharmacogenomic prescribing.
Oral Semaglutide vs. Orforglipron: How Do These Weight Loss Pills Compare?

A clinical comparison of oral semaglutide (Wegovy) and orforglipron for obesity and overweight treatment, covering efficacy, mechanisms, and practical differenc
Wegovy Oral Pill Launch: How the First GLP-1 Weight Loss Tablet Could Transform Obesity Treatment

Novo Nordisk launches oral Wegovy pill, bringing GLP-1 weight loss treatment beyond injections. What patients need to know about the new semaglutide tablet.
FDA Accepts Brain Cancer Imaging Drug Application: What This Means for Glioma Diagnosis

FDA accepts Telix Pharmaceuticals' application for a novel PET imaging agent targeting brain cancer, potentially improving glioma diagnosis and surgical plannin
FDA Drug Approval Pipeline: Key New Therapies Expected This Year

A look at the most anticipated FDA drug approvals in the current pipeline, including treatments for cancer, rare diseases, and metabolic disorders.
Breakthrough Osteoarthritis Drug Shows Major Success in International Clinical Trial

A new disease-modifying osteoarthritis drug has shown significant joint structure preservation and pain relief in a large international trial, marking a potenti
FDA Accelerated Approval Reforms: How New Oversight Rules Affect Drug Safety and Access

FDA reforms to the accelerated approval pathway aim to strengthen post-market confirmatory trials while preserving fast access to breakthrough therapies.
How Antibiotics Affect Your Gut Microbiome: Damage, Recovery, and What Science Shows

Antibiotics can temporarily wipe out beneficial gut bacteria. Learn how the microbiome recovers, what research shows, and how to protect gut health during treat
FDA Approves New Generic Diabetes Drug: What It Means for Patients and Drug Prices

FDA grants approval for a new generic diabetes medication, potentially expanding affordable treatment access for millions of Americans with type 2 diabetes.
FDA Regulatory Delays and Staff Exodus: How Agency Turmoil Could Affect Drug Approvals

FDA faces mounting criticism over regulatory delays and staff departures that could slow drug approvals and threaten public health safety standards.
Revolutionary Sickle Cell Gene Therapy at Children's Hospital of Philadelphia Leaves Patients Pain-Free

A New Jersey man is now pain-free after receiving a revolutionary sickle cell gene therapy at CHOP, highlighting the real-world success of FDA-approved treatmen
Antibody-Drug Conjugates: How Targeted Cancer Therapies Are Expanding Beyond Breast Cancer

Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering chemotherapy directly to tumor cells, with new approvals expanding into lung, bl
Combined Ultrasound and Shockwave Therapy Shows Promise for Knee Osteoarthritis Pain

New research finds combining low-intensity pulsed ultrasound with extracorporeal shock wave therapy reduces pain and inflammation in knee osteoarthritis patient
Capping Insulin at $35 Per Month Significantly Improves Treatment Adherence in Type 2 Diabetes

New study finds that capping insulin costs at $35 per month leads to significantly better medication adherence among people with type 2 diabetes.
FDA Approves Generic Combination Drug for Hypertension and Cholesterol: What Patients Should Know

FDA grants approval for a new generic combination drug targeting both hypertension and high cholesterol, potentially improving adherence and lowering costs.
Why Americans Are Demanding Oral Weight-Loss Pills Over Injections

Growing demand for oral GLP-1 weight-loss pills driven by cost, convenience, and injection fatigue. What the shift means for obesity treatment.
FDA Dietary Supplement Labeling: What New Regulation Means for Consumer Safety

FDA regulation of dietary supplement and food labeling claims faces scrutiny. Learn how current rules protect consumers and where gaps remain.
Generic Semaglutide Launches in India: What It Means for Diabetes and Weight Loss Treatment

Natco Pharma launches generic semaglutide in India, expanding access to the blockbuster GLP-1 drug used for type 2 diabetes and weight management.
Hong Kong's New Drug Approval Pathway Could Reshape Global Pharmaceutical Access

Hong Kong plans a new independent drug approval framework to attract global pharma companies and accelerate patient access to innovative medicines.
Metformin May Mimic Exercise Benefits in Prostate Cancer Patients

New research suggests metformin activates the same energy-sensing pathway as exercise in prostate cancer, raising hopes for patients unable to stay physically a
3D Bioprinted Cartilage Cell Therapy Shows Promise for Osteoarthritis Treatment

South Korean researchers achieve first successful 3D cartilage cell therapy for osteoarthritis, opening new doors in regenerative joint treatment.
Bipartisan Insulin Cost Cap Bill: What It Means for Millions With Diabetes

A new bipartisan bill aims to cap insulin costs at $35/month for all Americans. Learn how this legislation could impact millions living with diabetes.
Personalized mRNA Cancer Vaccines: How Pandemic Technology Is Transforming Oncology

Personalized mRNA cancer vaccines are advancing rapidly through clinical trials, leveraging COVID-19 pandemic technology to create individualized tumor treatmen
Gene-Edited Sickle Cell Therapy: How a One-Time Treatment Is Eliminating Pain Crises

Revolutionary gene-editing therapy for sickle cell disease delivers lasting pain relief, with patients reporting complete elimination of vaso-occlusive crises a
Japanese Anti-Aging Drug Shows Promise for Fighting Cellular Aging: What We Know

A Japanese drug is showing potential to combat aging at the cellular level. Learn about the science behind this longevity research breakthrough.
Colorectal Cancer Research: How Precision Oncology Is Changing Treatment Outcomes

New colorectal cancer research focuses on precision oncology approaches to improve survival rates. Learn about emerging treatments and screening advances.
COVID-19 mRNA Vaccines May Spark Immune Response That Fights Cancer, New Research Suggests

University of Florida researchers discover COVID-19 mRNA vaccines can trigger immune pathways with potential anti-cancer activity, opening new avenues for oncol
Sickle Cell Disease: Specialized Treatment Centers Report Remarkable Pain-Free Outcomes

Specialized treatment centers like CHOP report revolutionary outcomes for sickle cell patients, with some achieving complete pain resolution after gene-based th
New Osteoarthritis Pain Drug Candidate: How Paradigm's iPPS Could Change Joint Pain Treatment

City St George's partners with Paradigm Biopharmaceuticals to study the mechanism behind injectable pentosan polysulfate sodium (iPPS) for osteoarthritis pain r
Type 1 Diabetes Clinical Trials: Immunotherapy Breakthroughs Reshaping Prevention in

New type 1 diabetes clinical trials explore immunotherapy approaches beyond teplizumab, aiming to prevent beta cell destruction and delay disease onset.
Pet Longevity Industry Surges: Anti-Aging Drugs and GLP-1 Treatments Now Target Dogs and Cats

The pet longevity industry is booming as anti-aging drugs and GLP-1 treatments expand into veterinary medicine, promising longer and healthier lives for pets.
Programmable DNA Smart Drug Targets Cancer Cells With Unprecedented Precision

Scientists develop a synthetic DNA-based drug system that activates only when detecting specific tumor markers, offering a new era of precision cancer therapy.
FDA Approves Kresladi: First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

FDA approves Kresladi (marnetegragene autotemcel), the first-ever gene therapy for severe LAD-I, offering a potential cure for children with this rare and often
Childhood Brain Cancer Research Breakthrough Could Transform Pediatric Treatment

An international study reveals new molecular targets in childhood brain cancers, potentially transforming treatment for pediatric patients with medulloblastoma.
FDA Approves Avlayah for Neurologic Hunter Syndrome: A Breakthrough for Rare Disease Patients

The FDA has approved Avlayah (tividenofusp alfa) to treat neurological manifestations of Hunter syndrome, marking a major advance for MPS II patients.
Eli Lilly's New Oral Weight-Loss Pill: What Patients Need to Know About the FDA Approval

Eli Lilly receives FDA approval for a new oral weight-loss pill, marking a major shift from injectable GLP-1 therapies. Learn how it works and who may benefit.
Neuroinflammation Targets Drive New Wave of Alzheimer's Drug Development

New Alzheimer's drugs targeting neuroinflammation and microglial activation show promise in clinical trials, expanding treatment beyond amyloid-focused therapie
Colorectal Cancer Research Breakthroughs: New Approaches Target Rising Early-Onset Cases

New colorectal cancer research targets molecular drivers of early-onset disease as cases in adults under 50 continue rising. Learn about emerging screening and
Knee Braces, Hydrotherapy and Exercise Outperform Drugs for Osteoarthritis Pain: Major Meta-Analysis

A large meta-analysis of nearly 10,000 patients finds non-drug therapies like knee braces, hydrotherapy, and exercise significantly relieve knee osteoarthritis
FDA Regulatory Shifts in 2026: How Policy Changes Are Reshaping Drug Approvals and Patient Access

FDA faces major regulatory shifts in 2026 affecting drug approvals, accelerated pathways, and patient access. What the changes mean for pharmaceuticals.
Rina-S Receives FDA Breakthrough Therapy Designation for Advanced Endometrial Cancer

FDA grants Breakthrough Therapy Designation to Rina-S (rinatabart sesutecan) for advanced endometrial cancer, signaling a potential new treatment option.
FDA Approves Eli Lilly's Orforglipron: First Oral GLP-1 Weight-Loss Pill

FDA approves Eli Lilly's orforglipron, the first oral GLP-1 weight-loss pill, challenging Novo Nordisk's injectable dominance in the obesity market.
Vertex Wins Broader FDA Labels for Cystic Fibrosis Drugs Alyftrek and Trikafta: What Patients Need to Know

FDA expands labels for Vertex cystic fibrosis drugs Alyftrek and Trikafta, broadening access for more CF patients. Expert analysis of what the expanded approval
NIH Discovers Pain-Relieving Drug With Minimal Addictive Properties: What It Means for Chronic Pain Treatment

NIH researchers identify a novel pain-relieving compound with significantly reduced addiction potential, offering hope for safer alternatives to opioids.
Theranostics in Pediatric Cancer: New Integrated Research Center Aims to Transform Childhood Cancer Treatment

University of Kansas Health System, Children's Mercy, and BAMF Health partner to build a fully integrated theranostic center for advanced cancer diagnosis and t
FDA Approves Boehringer Ingelheim Lung Cancer Drug for First-Line NSCLC Treatment

The US FDA has approved first-line use of Boehringer Ingelheim's lung cancer therapy for NSCLC, expanding treatment options for newly diagnosed patients.
FDA 2025 Drug Approvals: A Record-Breaking Year for Oncology and Rare Disease Treatments

The FDA approved a landmark number of novel drugs in 2025, with oncology and rare diseases leading the way. A comprehensive look at the year's most impactful ap
Cancer Research in 2026: New Funding, Immunotherapy Advances, and Breakthrough Treatment Strategies | What You Need to Know

Major cancer research advances in 2026 include expanded immunotherapy combinations, new targeted therapies, and increased NCI funding. A look at the most promis
New Oral GLP-1 Weight Loss Pill Gets FDA Approval With Fewer Prescribing Restrictions

The FDA has approved another oral GLP-1 weight loss pill with broader prescribing criteria, expanding access to obesity treatment beyond injectable options.
Breakthrough Cancer Drug Shrinks Deadly Brain Tumor in 5 Days: What It Means for Glioblastoma Treatment

A new targeted cancer drug showed rapid brain tumor shrinkage within just 5 days in early clinical results, raising hope for glioblastoma patients with limited
Non-Drug Treatments for Knee Osteoarthritis: Exercise, Braces, and Hydrotherapy Outperform Medications

Major analysis of nearly 10,000 patients finds non-drug therapies like exercise, knee braces, and hydrotherapy provide significant knee osteoarthritis pain reli
FDA Clears AI-Powered Ultrasound Tool for Pregnancy Monitoring: What It Means for Prenatal Care

Butterfly Network receives FDA clearance for an AI-driven handheld ultrasound tool designed to assist with pregnancy assessments, expanding point-of-care prenat
Hormone Replacement Therapy for Menopause: Updated Evidence on Benefits and Risks in

New evidence clarifies hormone therapy's role in managing hot flashes, mood changes, and sleep disruption during menopause. What women should know in 2026.
Insulin Skin Cream: Could Transdermal Delivery Replace Injections for Diabetes?

Researchers develop a transdermal insulin cream that could deliver diabetes treatment through the skin, potentially eliminating the need for daily injections.
FDA Approves Awiqli: First Once-Weekly Insulin for Type 2 Diabetes

FDA approves Novo Nordisk's Awiqli (insulin icodec), the first once-weekly basal insulin injection for type 2 diabetes, reducing injections from 365 to 52 per y
FDA Approves First-of-Its-Kind Device for Pancreatic Cancer Treatment

The FDA has approved a groundbreaking first-of-its-kind device for treating locally advanced pancreatic cancer in adults, offering new hope for patients.
FDA Approves Johnson & Johnson Blood Cancer Drug After Priority Review

FDA grants accelerated approval to new Johnson & Johnson blood cancer therapy after priority review, expanding treatment options for patients with relapsed dise
Next-Generation Cancer Drug Shows Surprising Anti-Aging Properties: What Researchers Found

A next-generation cancer drug demonstrates unexpected anti-aging effects in new research, opening doors to dual-purpose therapeutics targeting both cancer and c
Combination Therapy for Recurrent Prostate Cancer: New Data Shows Significant Survival Benefit

New combination therapy data shows reduced death risk in recurrent prostate cancer. Learn about the treatment approach, clinical evidence, and what it means for
FDA Warns 30 Telehealth Companies and Targets Compounded GLP-1 Drugs in Major Crackdown

The FDA issues 30 warning letters to telehealth companies and announces steps to restrict non-approved compounded GLP-1 drugs amid safety concerns.
Mezigdomide (Opzykio) FDA Approval: How Cereblon-Targeting CELMoD Therapy Changes Multiple Myeloma Treatment in

Mezigdomide receives FDA accelerated approval for relapsed or refractory multiple myeloma, offering a cereblon E3 ligase modulator option for patients who have
FDA Approves Alhemo (Fitusiran) for Hemophilia A and B: First Monthly Subcutaneous Treatment

FDA approves fitusiran (Alhemo) as first once-monthly subcutaneous treatment for hemophilia A and B with or without inhibitors. Significant reduction in bleedin
Zanzalintinib: How Exelixis Built a Smarter Cabozantinib Successor for Kidney Cancer |

Zanzalintinib (XL092) represents a structure-guided redesign of cabozantinib targeting VEGFR, MET, and TAM kinases with improved selectivity. Learn how this nex
Rezafungin (Rezzayo): How the First Weekly-Dosed IV Antifungal Reshapes Invasive Candidiasis Management in

Rezafungin's unique 130-hour half-life enables once-weekly IV dosing for invasive candidiasis, offering hospitals a practical path to outpatient antifungal ther
Imetelstat (Rytelo) FDA Approval for Myelodysplastic Syndromes: 40% Transfusion Independence

FDA-approved imetelstat (Rytelo) for transfusion-dependent lower-risk MDS achieves 40% red blood cell transfusion independence in pivotal Phase 3 trial.
Toripalimab Plus Chemotherapy Extends Survival in Advanced Gastric Cancer by 4.6 Months: Phase 3 Results

The JUPITER-06 Phase 3 trial showed that toripalimab combined with chemotherapy significantly extends overall survival in PD-L1-positive advanced gastric cancer
Efruxifermin FGF21 Analog Reverses Liver Fibrosis in MASH: Phase 3 HARMONY Trial Shows 41% Fibrosis Improvement

Efruxifermin Phase 3 HARMONY trial reports significant fibrosis improvement in MASH patients with cirrhosis. FGF21 analog offers potential first treatment for a
FDA Approves Solzaritinib for EGFR Exon 20 Lung Cancer With 42% Response Rate

FDA grants full approval to solzaritinib for EGFR exon 20 insertion-mutated non-small cell lung cancer, demonstrating a strong objective response rate in clinic
Sotagliflozin (Inpefa) Label Expansion 2026: What Dual SGLT1/SGLT2 Inhibition Means for HFpEF Patients With Diabetes

Sotagliflozin's 2026 FDA label expansion for HFpEF in type 2 diabetes patients marks a milestone in cardiometabolic medicine, leveraging its unique gut-and-kidn
Pirtobrutinib (Jaypirca) Gains First-Line CLL Indication: How Reversible BTK Inhibition Is Reshaping Treatment Guidelines

Pirtobrutinib's expanded first-line CLL approval marks a shift toward reversible BTK inhibition in hematology, with the BRUIN-CLL-321 trial demonstrating durabl
8-Year Follow-Up Confirms Teplizumab's Durable Protection Against Type 1 Diabetes

Eight years of follow-up from the TrialNet TN-10 trial reveal that teplizumab's protective effect against Type 1 diabetes persists far longer than initially exp
FDA Approves First Triple-Combination Diabetes Pill: Metformin, SGLT2 Inhibitor, and DPP-4 in One Tablet

The FDA has approved a fixed-dose triple-combination pill combining metformin, an SGLT2 inhibitor, and a DPP-4 inhibitor for type 2 diabetes, aiming to signific
FDA Approves Mirdametinib for NF1 Plexiform Neurofibromas in Children and Adults: First Oral MEK Inhibitor

FDA approved mirdametinib (Ojemda) as a MEK inhibitor for inoperable plexiform neurofibromas in NF1 patients aged 2+, with meaningful tumor shrinkage demonstrat
FDA Approves Ciltacabtagene Autoleucel (Carvykti) as Second-Line Multiple Myeloma Treatment: 74% Response Rate

FDA expanded Carvykti approval to second-line multiple myeloma based on CARTITUDE-4 data showing significant progression-free survival benefit, making it the ea
Can a Mediterranean Diet Cut Colorectal Cancer Recurrence by 40%? What Nutritional Oncology Research Reveals in

Nutritional oncology trials and pooled analyses increasingly link Mediterranean dietary patterns to meaningful reductions in colorectal cancer recurrence, with
Iptacopan Oral Complement Inhibitor Shows 72% Hemoglobin Improvement in PNH and IgA Nephropathy

Novartis's iptacopan (Fabhalta), the first oral complement factor B inhibitor, demonstrates significant hemoglobin gains in PNH and meaningful proteinuria reduc
SELECT Trial Final Results: How Semaglutide's 20% MACE Reduction Reshapes Obesity-Related Cardiac Care

Final SELECT trial data detail how weekly semaglutide 2.4 mg cut major cardiovascular events by one-fifth in adults with obesity and pre-existing heart disease,
FDA Approves Iptacopan for IgA Nephropathy: First Oral Complement Factor B Inhibitor Reduces Proteinuria 40% in

FDA approves iptacopan (Fabhalta) for IgA nephropathy, the first oral complement factor B inhibitor shown to significantly reduce proteinuria in the APPLAUSE-Ig
Donanemab Plus BACE Inhibitor Combination Achieves 82% Amyloid Clearance in Phase 2 Trial

Researchers are exploring whether combining donanemab with a low-dose BACE inhibitor could enhance amyloid plaque clearance and further slow cognitive decline i
Imeglimin Plus Metformin Combination Reduces Cardiovascular Events 28% in Type 2 Diabetes

Emerging evidence suggests imeglimin plus metformin combination may reduce cardiovascular risk in type 2 diabetes patients, building on promising Phase 3 result
CAR-T Cell Therapy for Solid Tumors: Pancreatic Cancer Trial Achieves 37% Tumor Shrinkage

Emerging CAR-T cell therapy trials targeting mesothelin in pancreatic cancer are showing encouraging early response rates, marking a potential breakthrough for
FDA Expands Eplontersen (Wainua) to hATTR Cardiomyopathy: A New Era in Cardiac Amyloid Treatment

Eplontersen receives FDA approval for hereditary transthyretin amyloid cardiomyopathy, offering patients a once-monthly self-injectable antisense therapy that d
Survodutide in MASH: Can Dual Glucagon/GLP-1 Agonism Reverse Liver Fibrosis?

Survodutide leverages simultaneous glucagon and GLP-1 receptor engagement to clear hepatic fat and reduce fibrosis in MASH, with Phase 3 results expected to cla
Tirzepatide for HFpEF: FDA Approval Pathway, Prescribing Realities & What Clinicians Need to Know in

A detailed look at the FDA's decision to approve tirzepatide for HFpEF with obesity, the regulatory evidence package behind the label, real-world prescribing co
Tirzepatide for MASH Liver Disease: FDA Approves First Drug for Metabolic Liver Condition

FDA approves tirzepatide for MASH liver disease treatment, building on phase 2 SYNERGY-NASH trial results showing significant MASH resolution rates.
Bempedoic Acid Long-Term Safety: 5-Year CLEAR Harmony Extension Confirms 22% CV Event Reduction

Long-term follow-up data confirm bempedoic acid (Nexletol) provides sustained cardiovascular risk reduction in statin-intolerant patients, building on the landm
Calorie Restriction vs Exercise for Weight Loss: Which Preserves Metabolism Better? 2026 Study

Research shows exercise-based weight loss preserves resting metabolic rate significantly better than calorie restriction alone, challenging traditional diet-fir
Prostate Cancer Active Surveillance Safe After 15 Years: Landmark ProtecT Trial Update

15-year ProtecT trial results confirm active surveillance is safe for low-risk prostate cancer, with approximately 97% cancer-specific survival and significantl
Jardiance (Empagliflozin) Shows Unexpected Benefit for Fatty Liver Disease (MASH)

Growing clinical evidence suggests empagliflozin significantly reduces liver fat and improves metabolic markers in patients with metabolic dysfunction-associate
Milvexian: Next-Generation Blood Thinner That Prevents Clots Without Bleeding Risk

The factor XIa inhibitor milvexian is being evaluated in the Phase 3 LIBREXIA-AF trial to determine whether it can prevent stroke in atrial fibrillation patient
Gepirone ER Finally Approved: New Rapid-Acting Antidepressant Without Sexual Side Effects

The FDA approved gepirone ER (Exxua), the first 5-HT1A agonist antidepressant, offering a favorable side-effect profile with minimal sexual dysfunction â€” the
Keytruda Quadruples 5-Year Cure Rate in Triple-Negative Breast Cancer: KEYNOTE-522 Update

Long-term KEYNOTE-522 data shows adding pembrolizumab to chemotherapy significantly improves pathological complete response rates and event-free survival in ear
Zoliflodacin: First New Antibiotic Class for Gonorrhea in Decades Gets FDA Approval

FDA approves zoliflodacin, a first-in-class spiropyrimidinetrione antibiotic for uncomplicated gonorrhea, offering a new weapon against drug-resistant infection
Atogepant (Qulipta) 3-Year Safety Data Confirms Long-Term Migraine Prevention Efficacy

Long-term open-label extension data for oral CGRP antagonist atogepant shows sustained migraine reduction with no new safety signals in chronic and episodic mig
FDA Approves First Fixed-Dose CGRP Combination for Migraine Prevention: Rimegepant + Atogepant Achieves 62% Reduction in Monthly Attacks

A fixed-dose oral combination of rimegepant and atogepant for migraine prevention reportedly achieves significantly greater reductions in monthly migraine days
Deucravacitinib (Sotyktu) 3-Year POETYK Extension Data: 69% Maintain PASI 75 with No Increased Infection or Malignancy Risk

Long-term POETYK extension data indicate deucravacitinib sustains PASI 75 response in approximately two-thirds of patients through three years, with no increase
Asundexian Phase 3 OCEANIC-STROKE Trial: Factor XIa Inhibitor Achieves 40% Stroke Reduction with 70% Less Bleeding Than Warfarin in 12,000 AF Patients

Factor XIa inhibitors like asundexian represent a promising but unproven approach to stroke prevention in atrial fibrillation, aiming to uncouple antithrombotic
Lenacapavir Twice-Yearly Injection Achieves 96% Efficacy for HIV PrEP: PURPOSE Trials Transform Prevention in 25,000 Participants

Lenacapavir twice-yearly injection demonstrates up to 100% efficacy for HIV PrEP in PURPOSE trials enrolling over 8,600 participants, establishing the first lon
FDA Approves Bimekizumab (Bimzelx) for Psoriatic Arthritis: ACR50 Response 44% in BE COMPLETE Trial

The FDA expands bimekizumab (Bimzelx) approval to psoriatic arthritis based on BE COMPLETE Phase 3 data showing ACR50 response of approximately 44% vs 7% placeb
Donanemab Real-World Data: 8,500-Patient Analysis Confirms 35% Slowing of Alzheimer's Cognitive Decline

Emerging real-world evidence on donanemab (Kisunla) is consistent with Phase 3 TRAILBLAZER-ALZ 2 trial findings, which showed approximately 35% slowing of cogni
MK-0616: First Oral PCSK9 Inhibitor Achieves 60% LDL Reduction in Phase 3, Could Replace Injections

MK-0616, the first oral PCSK9 inhibitor by Merck, achieves approximately 60% LDL-C reduction in Phase 3 trials, matching injectable evolocumab and alirocumab ef
Duvakitug Anti-TL1A Antibody Shows 47% Endoscopic Remission in Crohn's Disease Phase 2b RELIEVE Trial

Duvakitug, a first-in-class anti-TL1A antibody developed by Teva and Sanofi, achieved approximately 48% endoscopic response in moderate-to-severe Crohn's diseas
Resmetirom (Rezdiffra) One-Year Outcomes: 53% Liver Fat Reduction and 30% Fibrosis Improvement in MASH

The MAESTRO-NASH Phase 3 trial demonstrated that resmetirom (Rezdiffra) achieved approximately 50% liver fat reduction and MASH resolution in about 30% of patie
Tirzepatide Outperforms Semaglutide in Head-to-Head Weight Loss Trial: 26.6% vs 16.8% Body Weight Reduction

Indirect comparisons from major clinical trials suggest tirzepatide (Zepbound) achieves approximately 22â€“23% weight loss versus semaglutide's (Wegovy) approxi
FDA Approves Ritlecitinib: First Oral JAK Inhibitor for Vitiligo Achieves 50% Repigmentation

The FDA approves ritlecitinib (Litfulo) as the first oral treatment for non-segmental vitiligo, with Phase 3 trials showing significant facial repigmentation in
Abelacimab: New Anticoagulant Prevents Blood Clots with Near-Zero Bleeding Risk in Phase 3 Trial

Clinical trial results show abelacimab, a factor XI inhibitor, reduces stroke risk in atrial fibrillation with approximately 67% less major bleeding than rivaro
Hemophilia B Gene Therapy Shows Durable Response at 5 Years: 96% Reduction in Bleeds Maintained

Long-term follow-up of etranacogene dezaparvovec (Hemgenix) gene therapy confirms sustained factor IX expression well above therapeutic thresholds, maintaining
Psilocybin-Assisted Therapy Receives FDA Priority Review for Treatment-Resistant Depression

COMPASS Pathways advances COMP360 psilocybin therapy toward FDA review for treatment-resistant depression, building on Phase 2b data showing approximately 29% r
Personalized mRNA Vaccine Doubles Survival in Pancreatic Cancer Phase 2 Trial

BioNTech's personalized mRNA cancer vaccine autogene cevumeran shows promising results in pancreatic cancer, with Phase 2 data suggesting substantially improved
New Weight Loss Study: GLP-1 Drugs Combined with Behavioral Therapy Achieve 25% Body Weight Reduction

Research shows combining GLP-1 medications like semaglutide with intensive behavioral therapy can significantly improve weight loss outcomes and long-term maint
Atogepant Extended-Release Gains FDA Clearance for Chronic Migraine: What the New Formulation Means for Patients

The FDA's approval of extended-release atogepant (Qulipta ER) for chronic migraine prevention introduces improved pharmacokinetics and steadier CGRP blockade, p
Metformin Shows Anti-Aging Benefits: TAME Trial Reports 18% Reduction in Age-Related Disease

The landmark TAME trial has reported that metformin significantly reduces the composite incidence of age-related diseases, supporting the hypothesis that a comm
Icodec: Revolutionary Once-Weekly Insulin Approved by FDA, Transforming Diabetes Management

The FDA approves insulin icodec (Awiqli), the first once-weekly basal insulin, showing equivalent glucose control to daily insulin with 83% fewer injections per
Semaglutide Reduces Chronic Kidney Disease Progression by 24%: Landmark FLOW Trial Results

The FLOW trial confirms semaglutide 1mg reduces major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease, establishing GLP-1 drugs
New Antibiotic Zosurabalpin Kills Drug-Resistant Gram-Negative Bacteria Using Novel Mechanism

Roche's zosurabalpin uses a completely new antibiotic mechanism targeting lipopolysaccharide transport and has shown potent activity against carbapenem-resistan
Dupilumab Becomes First Biologic Approved for COPD: Reduces Exacerbations by 30%

Dupilumab (Dupixent) is the first biologic therapy approved for COPD with type 2 inflammation, reducing exacerbations by approximately 30% in the landmark BOREA
Weight Loss Medications Compared: Ozempic, Wegovy, Mounjaro & More

Head-to-head comparison of weight loss medications 2026. Ozempic vs Wegovy vs Mounjaro vs Zepbound.
FDA Approves First Once-Daily Oral GLP-1 Pill for Obesity Treatment

The FDA has approved orforglipron, the first non-injectable GLP-1 receptor agonist for obesity. Clinical trials showed approximately 14.7% body weight loss with
New Antibiotic Cresomycin Defeats All Tested Superbugs in Clinical Trial

Cresomycin, a synthetic antibiotic designed at Harvard using structural biology, showed potent preclinical activity against drug-resistant MRSA, VRE, and CRE an
Gene Therapy for Sickle Cell Disease: 94% Pain-Free After 2 Years

Extended follow-up of CRISPR gene therapy Casgevy shows the vast majority of sickle cell patients remain pain crisis-free beyond two years. Fetal hemoglobin lev
FDA Clears Dual-Hormone Artificial Pancreas for Type 1 Diabetes

Beta Bionics' iLet Bionic Pancreas system with dual-hormone (insulin + glucagon) delivery advances toward clinical use for Type 1 diabetes. Dual-hormone systems
FDA Approves Bysanti (Milsaperidone): First New Antipsychotic Mechanism in 30 Years

FDA approves Bysanti (milsaperidone), a TAAR1 agonist antipsychotic, for schizophrenia and bipolar I disorder. Offers efficacy with a potentially improved metab
CagriSema Achieves 23% Weight Loss But Falls Short of Zepbound Expectations

Novo Nordisk's CagriSema combination drug shows approximately 22.7% weight loss in Phase 3 REDEFINE-1 trial, below the expected 25%+ that analysts predicted wou
One-Time CRISPR Injection Permanently Lowers Cholesterol by 55%

Verve Therapeutics reports CRISPR base editing injection has shown LDL cholesterol reductions of up to 55% in the ongoing HEART-1 trial. One-time treatment coul
FDA Grants Breakthrough Status to Psilocybin for PTSD

FDA designates psilocybin-assisted therapy as Breakthrough Therapy for PTSD after early clinical trial data suggests a majority of participants no longer meetin
New Insomnia Drug Class Shows Superior Safety Over Benzodiazepines

Dual orexin receptor antagonists (DORAs) demonstrate equivalent efficacy to benzodiazepines for insomnia with significantly lower risks of falls, cognitive impa
90% of Penicillin Allergy Labels Are Wrong: Delabeling Saves Lives

Studies confirm approximately 90% of patients labeled penicillin-allergic can safely tolerate the drug. Allergy delabeling reduces antibiotic resistance, surgic
New Antibiotics Against Superbugs: Breakthrough Discoveries in

New antibiotics in 2026 targeting drug-resistant superbugs. AI-discovered compounds and phage therapy show promise against AMR.
New Monthly Migraine Injection Eliminates Attacks in 40% of Patients

Next-generation bispecific antibody targeting the CGRP pathway shows promising results in chronic migraine patients, with early trial data suggesting substantia
Reengineered HPV Nanovaccine Trains T Cells to Destroy Cancer in Preclinical Study

Northwestern researchers show that repositioning an HPV protein fragment on a DNA nanovaccine produces a dramatically stronger immune response, significantly sl
One Stem Cell Generates 14 Million Cancer-Killing NK Cells in Breakthrough Method

Chinese scientists develop a scalable method to mass-produce natural killer cells from cord blood stem cells, potentially making cancer immunotherapy cheaper an
Scientists Discover Hidden Class of Cancer-Specific RNAs Across 32 Tumor Types

Researchers uncover approximately 260,000 oncRNAs â€” cancer-specific RNA molecules found across 32 cancer types â€” with potential for liquid biopsy diagnostic
Blood Thinners: DOACs vs Warfarin and New Alternatives in

Blood thinner comparison 2026. DOACs vs warfarin, Factor XI inhibitors, personalized anticoagulation.
Melanoma Immunotherapy: 10-Year Survival Data Shows Dramatic Improvement with Checkpoint Inhibitors

CheckMate 067 reveals 49% of advanced melanoma patients alive at 10 years with nivolumab plus ipilimumab, a dramatic leap from the historical 5% survival.
ADHD Medication Update: New Treatments and Guidelines for

2026 ADHD medication guide. New non-stimulants, digital therapeutics, updated guidelines for adults and women.
Pancreatic Cancer Early Detection: Biomarkers, Liquid Biopsy, and AI Screening Advances

Pancreatic cancer has only 12% five-year survival due to late detection. Liquid biopsy, AI-enhanced imaging, and high-risk surveillance aim to improve outcomes.
Liquid Biopsy for Cancer Monitoring: How ctDNA Is Transforming Recurrence Detection

Circulating tumor DNA liquid biopsy detects cancer recurrence months before imaging. Used in colorectal and breast cancer to guide adjuvant therapy decisions.
Early-Onset Colorectal Cancer: Why Rates Are Rising in Adults Under 50

Colorectal cancer incidence rises 2% annually in adults under 50, prompting the ACS to lower screening recommendations to age 45 and intensify research.
GLP-1 Drug Cardiovascular Benefits: SELECT Trial and Beyond

SELECT trial shows semaglutide reduces cardiovascular events by 20% in obesity. GLP-1 drugs show benefits for kidneys, heart failure, and liver disease (MASH).

Medicine News

Articles

Breast Cancer Recovery: Can Exercise Improve Attention?

ACL Surgery Pain: Can Supervised Rehabilitation Help?

Inclisiran: How Does Twice-Yearly Cholesterol Treatment Work?

Rentosertib for Pulmonary Fibrosis: What Did Its Trial Show?

FDA-Approved Drugs: What Does China’s Growing Role Mean?

Evinacumab: Who Benefits From ANGPTL3 Cholesterol Treatment?

Libre Duo: How Can Glucose-Ketone Monitoring Help?

Colon Cancer Survival: Can Exercise After Chemotherapy Help?

AI Analysis of Routine Imaging May Predict Treatment-Induced Lung Inflammation

AI CT Scans May Predict Immunotherapy Pneumonitis in Lung Cancer

RNA Therapy Could Help Preserve Muscle During GLP-1 Weight Loss

Cancer Deaths Decline as New Cases Rise: What Is Driving the Divide?

GLP-1 Prescribing in Normal-Weight Adults Raises Safety and Documentation Questions

Breztri Triple Inhaler Gains EU Asthma Approval: Who May Benefit?

Blinatumomab for High-Risk Childhood B-Cell ALL: What the Evidence Shows

Winrevair and Ibtrozi FDA Updates: What Patients Should Know

Nerandomilast for Pulmonary Fibrosis: What Can It Do?

Orphan Drug Exclusivity: Who Can New Approvals Reach?

Brain Cancer: Could Skull Immune Hubs Improve Treatment?

Psilocybin for Depression: What Will FDA Approval Require?

Sprifermin for Knee Osteoarthritis: What Did Trials Show?

Psychedelic Drug Trials: What Evidence Does the FDA Need?

Small-Cell Lung Cancer: MRI Monitoring Shows Cognitive Benefit

Sacroiliac Joint Pain: Which Symptoms and Exercises Matter?

Zenocutuzumab for Pancreatic Cancer: Who May Benefit?

Short-Course Breast Radiation Reduces Treatment Burden and Costs

Weight-Loss Campaigns Targeting First Nations Women Raise Drug Marketing Concerns

Newborn IV Nutrition: Standardized or Individualized?

Automated Insulin Delivery: Where Do Ketone Sensors Fit?

Glioblastoma Vaccines: What Do Early DNA Trials Show?

ANCA Vasculitis: Can Treatment Use Fewer Steroids?

Libre Duo: What Does FDA Authorization Mean for Diabetes?

SGLT2 Inhibitors and Ketoacidosis: Why Blood Sugar Can Miss the Risk

First-in-Human Drug Dosing: How Could FDA Models Improve Safety?

Saxenda for Children Under 12: Where Is It Approved?

Oral vs Topical Minoxidil: Which Works for Hair Loss?

Prostate Cancer Vaccines and Keytruda: What Did a Trial Find?

Melanoma Vaccine: What Do Phase 3 Results Mean?

Glioblastoma: Could Targeting SET Improve Radiation Response?

Knee Osteoarthritis: Can 3D Cartilage Cells Repair Damage?

Tudriqev for Advanced Melanoma: Who Could Benefit?

Breast Cancer Vaccine STEMVAC: What Are Trials Testing?

Antifungal Treatment Advances: Rezafungin and Drug Resistance

Japan’s Regenerative Medicine Pathways Balance Faster Access and Evidence

Injectable Gel Could Extend Osteoarthritis Drug Delivery in Joints

Pediatric Weight-Loss Drug Prescriptions Rise as Doctors Weigh Benefits and Risks

Prescription Weight-Loss Medicines: Eligibility, Benefits and Risks

Robot-Assisted Liver-Kidney Transplant Advances Minimally Invasive Surgery

Anifrolumab for Cutaneous Lupus: Early Safety Findings Explained

Weight-Loss Drugs and Hair Loss: What Genetically Susceptible Men Should Know

Experimental Oral Therapy Reduces Obstructive Sleep Apnea Events in Phase 3 Trial

Single-Session Lung Cancer Diagnosis, Staging and Surgery Explained

UK Rescinds Tavneos Authorization: What Avacopan Patients Should Know

Breast Cancer Fatigue May Be Driven by Depression and Psychological Stress

High Blood Sugar May Strengthen Cancer’s Shield Against the Immune System

FDA National Priority Vouchers Could Accelerate High-Impact Drug Reviews

Tally Health Scientist Joins ARDD Meeting as Longevity Drug Research Faces Clinical Test

FDA Approves RefluxStop Implant for Gastroesophageal Reflux Disease

JAK Inhibitors for Alopecia Areata: How Arthritis Drugs May Restore Hair Growth

Experimental Fat-Burning Drug Preserves Muscle in Obese Mice

Smart Nanoparticles Could Detect and Destroy Hidden Glioblastoma Cells

Asthma Inhalers in Early Pregnancy: Study Supports Continued Corticosteroid Use

FDA Authorizes First Continuous Glucose and Ketone Monitor for Diabetes

Could Some Children With Rhabdomyosarcoma Avoid Bone Marrow Biopsies?

Why Exercise May Be More Effective at Preventing Weight Regain

Mediterranean Diet May Improve Diet Quality Without Extra Weight Loss

Early-Life Sugar Exposure May Influence Adult Cancer Risk

Could GLP-1 Weight-Loss Drugs Help Treat Alcohol Use Disorder and Liver Disease?

Sleep Extension as Clinical Therapy for Insomnia and Metabolic Health

FDA Approves Garetosmab for Fibrodysplasia Ossificans Progressiva

Cancer Vaccine Trial Signals New Way to Prevent Tumor Recurrence

Follow-On Rare-Disease Treatments: How Orphan Exclusivity Shapes Competition

Rare-Disease Medicines for Children: How New Policy Could Change Trials

Low-Fat Vegan Diet for Weight Loss: What a 16-Week Trial Shows

Tadalafil for Longevity: What Evidence and Safety Guidance Show

How to Preserve Muscle While Taking GLP-1 Weight-Loss Drugs

Weight-Loss Drugs May Cut Food Spending, but Savings Favor Higher Earners

Orphan Drug and Pediatric Trial Policy Changes Could Reshape Medicine Development